

## **CURRICULUM VITAE**

**Name.** ANEGON, Ignacio

**Work adresse.** Institut National de la Santé Et de la Recherche Médicale (INSERM) UMR 1064-CRTI. 30, Bd. Jean Monnet. Nantes. 44093. France.  
Tel (02)40087415  
Fax (02)40087411  
E-mail ianegon@nantes.inserm.fr

### **EDUCATION.**

Medical Doctor by the University of Uruguay (1982).  
Diplôme HDR, 1998, Immunologie, Université de Nantes.

### **PROFESSIONAL APPOINTMENTS**

Post doctoral fellow at the Immunology Department, 1982-1985. Clinical Hospital of the University of Barcelona, Spain.

Associate Scientist at The Wistar Institute, University of Pennsylvania, 1985-1988.

Visiting Scientist at the INSERM Unit 211 (Poste vert), 1988-1989. Nantes, France.

Professor at the Programa de Desarrollo de Ciencias Basicas of Uruguay (UNESCO).

Permanent position, Charge de Recherche de 2<sup>ème</sup> et 1<sup>ère</sup> classe, INSERM U211 and U437, Nantes, France (1989-2002).

Team leader at INSERM unit since 1998.

Permanent position, Directeur de Recherche 2<sup>ème</sup> classe INSERM (2002-2009).

Visiting scientist, November-December 2005, Mount Sinai School of Medicine, New York, USA.

Permanent positions at INSERM as Chargé de Recherches de 2<sup>ème</sup> (1989) et 1<sup>ère</sup> classe, Directeur de Recherche de 2<sup>ème</sup> and 1<sup>ère</sup> classe and Directeur de Recherche de Classe Exceptionnelle (2020-present) at INSERM.

Director INSERM UMR643 and 1064 (2009-2019).

Director of the platform “Rat Transgenesis ImmunoPhenomic“ (French IBiSA program) (2002-present).

Co-director of the GenoCellEdit platform (INSERM U1064 and SFR Bonnamy) (2015-present).

Director FOCIS Center of Excellence University of Nantes (2002-present)

Deputy Director Labex Immunology Graft-Oncology (2012-2016).

Director Labex Immunology Graft-Oncology (2016-2020).

Prime Recherche Inserm (2014-present).

Chairman FOCIS Multinational Centers of Excellence Committee (2014-2018)

Co-Chairman FOCIS Educational Committee (2018-present)

Founder and Senior Consultant of AbolerIS Pharma (2020-present)

## **EDITOR OF BOOKS**

« **Rat genomics: gene identification, functional genomics and disease models**” (Editor: I. Anegon; Series: Methods in Molecular Biology; Editorial: Humana Press, USA), 2009.

“**Suppression and regulation of immune responses. Volume I**” (Editors: M. C. Cuturi and I. Anegon; Series: Methods in Molecular Biology; Editorial: Humana Press, USA) 2010.

“**Suppression and regulation of immune responses. Volume II**” (Editors: M. C. Cuturi and I. Anegon; Series: Methods in Molecular Biology; Editorial: Humana Press, USA) 2015.

## **EDITORIAL ACTIVITY IN SCIENTIFIC JOURNALS**

**Editor-in-Chief of “*Current Gene Therapy*” (2004-2017)**

<http://www.bentham.org/cgt/>. [Bentham Publishers (Oak Park, IL, USA), bimестrial, peer-reviewed, indexed en PubMed, impact factor 2012=5.31]

**Deputy Editor of the Basic Science section of *Transplantation*** (official journal of the international Transplantation Society) (2014-present)

**Associate Editor *Frontiers in Medicine* (2016-present).**

## **MEMBER EDITORIAL BOARDS**

*Immunologia* (Journal of the Spanish Society for Immunology) (1993-2000)

*European Cytokine Network* (Journal of the European Society of Cytokines)(1997-present).

*Transplantation* (Journal of The Transplantation Society International)(2000-2004).

*Current Gene Therapy* (2001-2003).

*Transgenic Research* (2005-present).

*Hepatobiliary Pancreat Dis Int* (2006-present).

*Transplant International* (Journal of the European Society for Organ Transplantation) (2009-present)

*Frontiers in Immunology* (2011-present)

*Scientific Reports* (2016-present)

*The Scientific Pages of Animal Biotechnology*

*BMC Biotechnology*

## **MEMBERSHIP OF SCIENTIFIC COMMITTEES**

- Scientific council Company Jouan for the prizes “Thérapie Génique” (1999-2008).
- Basic Science Committee of the European Society for Organ Transplantation (ESOT) (2003-2012).
- Coordinateur de la plate-forme “Exploration Fonctionnelle” de l’Ouest-Génopole (2002-2003).
- Scientific council of OUEST-Génopole (2003-2014).
- Comité d’Orientation Stratégiques et de Suivi des Essais Cliniques (Cossec) en biothérapies de l’INSERM (2005-2009).
- Basic Science Committee of The Transplantation Society (2006-2010)
- Representative of the INSERM unit 643 in the Nantes cluster of biomedical research laboratories (Institut Fédératif de Recherche 26 ‘Recherche Thérapeutique’)(2001-2012).
- Member of the steering committee of the “Centaure Foundation” (RTRS network on Transplantation Medical Science between University Hospitals from Nantes, Necker in Paris and E. Herriot in Lyon) 2007-2011.
- Member of the ESOT General Council as councillor from the Basic Science Committee (2007-2011).
- Member of the Scientific council of the Nantes School of Medicine (2008-2012)
- Member of the Commission Sciences de la Vie du « Comité Consultatif Régional de la Recherche et du Développement Technologique » (CCRRDT) Pays de la Loire (2008-2010).
- Representative of ESOT in the Federation of Clinical Immunology Societies (FOCIS) (2009-present).
- Chairman of the Multinational FOCIS Centers of Excellence network and Board of Directors of FOCIS (2015-2018).
- Co-chairman of the Educational Committee of FOCIS (2018-present)

## **MEMBER OF SCIENTIFIC ADVISORY BOARDS**

- Millenium Nucleus on Immunology and Immunotherapy from Chile (2006-2011)
- Berlin-Brandenburg Center for Regenerative Therapies (2013-2020).
- INSERM 1098 (Besançon) “Interactions hôte- griffon-tumeur et ingénierie cellulaire et génique”. (2016-present).
- Instituto Pasteur de Montevideo (2018-present)

**ORGANISATION OF SCIENTIFIC MEETINGS AND COURSES: 33 in France and international ones for Scientific Societies (FOCIS, ESOT, TTS and ISTT).**

**INVITED SEMINARS AND SCIENTIFIC MEETINGS: 132**

## **AREAS OF EXPERTISE**

- Immune tolerance
- Cellular immunology
- Gene transfer using viral vectors
- Generation of transgenic animals

## PUBLICATIONS

Total publications: 267

PubMed: 244

Google Scholar résumé (February 2021):

	Total	since 2016
Citations.	13529	4784
h-index.	63	33

- 1) Vignale RA, A. Perlas, I. Anegon, C. Cuturi, J. Paniel. Complejos inmunes circulantes en sífilis latente tratada. **Med. Cutan. Iber. Lat Am.** 1983. 11 (3) :205-210.
- 2) Gallart T., I. Anegon, S. Woessner, R. de la Fuente, L. Florenza, C. Sans-Sabrafen and J. Vives. Clinically benign adult T-cell chronic lymphocytosis with unusual phenotype. **Lancet** 1983. 1:769-770.
- 3) F. Cardellach, A. Pujol, A. Lopez Soto, I. Anegon, M.C. Cuturi, et al. Síndrome de inmunodeficiencia adquirido en fase prodromica en un drogadicto. **Med. Clin.** 1983. 81: 645.
- 4) Gallart T., I. Anegon, C. Cuturi, C. Mieras, G. Acevedo, S. Maragall, M. Vila, R. Castillo, J. Tringer, A. Gelabert, J. Vives. T lymphocyte subpopulations in Spanish haemophiliacs treated with commercial clotting factors concentrates. In: "**Epidemics of acquired immune deficiency syndrome (AIDS) and Kaposi's Sarcoma.**". C. Giraldo, E. Beth, eds. **Antibiotics and Chemotherapy.** 1984. Vol. 32 pp.153.
- 5) Urbano-Ispizua A., R. Struch-Riba, I. Anegon, T. Gallart, J. Blade, A. Urbano-Marquez and C. Rozman. Gammapatia monoclonal serica IgA-lambda en un paciente afecto de sarcoma inmunoblastico con inmunoglobulina de superficie celular IgM-kappa. **Med. Clin.** 1985. 16:405-407.
- 6) Cervantes F., I. Anegon, C. Rozman, T. Gallart, A. Pereyra, J. L. Vives-Corróns, J. Casademont, A. Urbano-Marquez. Early T-cell features in blast crisis of Ph-positive chronic myeloid leukemia. **Scand. J. Haematolo.** 1985. 35:71-76.
- 7) Anegon I., Vilella R., Gallart T., Cuturi M.C., Borche L., Mila J., Vives J. B-C1, B-C2, B-C3: Monoclonal Antibodies (MoAb) against B cell differentiation antigens. In "**Leukocyte Typing II**". E. Reinherz, Haynes, Nadler, Bernstein, Eds. **Springer-Verlag.** 1986. vol 2. pp 121-139.
- 8) Latorre X., Cuturi M.C., Miro J.M., Anegon I., Gastell J.M., Gallart T., Bruguera M., Pumarola T., Trilla A., Ginel J., Vives J. Lymphocyte subpopulations in Spanish parenteral drug addicts. **Scand J Infect Dis.** 1986. 18:71-78.
- 9) Perussia B., I. Anegon, M.C. Cuturi, M. Murphy, and G. Trinchieri. Mechanisms of regulation of hematopoiesis by human natural killer cells and T lymphocytes. In: "**Genotypic, phenotypic and functional aspects of haematopoiesis**". F. Grignani,

**M.F. Martelli and D.Y. Mason. Eds., Serono Symposium Publications from Raven Press, N.Y., 1987. vol. 41. pp. 275-280.**

- 10) Perussia B., M. Kobayashi, M. E. Rossi, I. Anegon and G. Trinchieri. Immune interferon enhances functional properties of human granulocytes: role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor. **J. Immunol.** **1987.** **138:765-774.**
- 11) Perussia, B., C. Ramoni, I. Anegon, M.C. Cuturi, J. Faust, and G. Trinchieri. Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B lymphoblastoid cell lines. **Nat. Immun. Cell Growth Reg.** **1987.** **6:171-188.**
- 12) Trinchieri, G., M. Murphy, M.C. Cuturi, I. Anegon, and B. Perussia. Control of hematopoietic progenitor cells by natural killer cells. **In: "Functions of the natural immune system", C. W. Reynolds and R. H. Wiltout, Eds., Plenum, N. Y. 1987.**
- 13) Anegon, I., M.C. Cuturi, G. Trinchieri, and B. Perussia. Fc receptor-ligand interaction induces activation of human natural killer cells. **In: "Major histocompatibility genes and their role in immune function", C. S. David, Ed., Plenum Press, N. Y. 1987. 815-825.**
- 14) Vives Corrons J. L., C. Rozman, M. A. Pujades, D. Colomer, E. P. Vila, I. Anegon, T. Gallart, J. Vives Puiggros, N. Vinolas and E. Montserrat. Combined assay of adenosine deaminase, purine nucleoside phosphorilase, and lactate dehydrogenase in the early evaluation of B-chronic lymphocytic leukemia. **Am. J. Hematol.** **1988.** **27:157-162.**
- 15) Anegon, I., M.C. Cuturi, G. Trinchieri and B. Perussia. Interaction of Fc receptor (CD16) with ligands induces transcription of IL-2 receptor (CD25) and lymphokines genes and expression of their products in human natural killer cells. **J. Exp. Med.** **1988.** **167:452-472.**
- 16) Cassatella, M. A., I. Anegon, M. C. Cuturi, G. Trinchieri, and B. Perussia. FcR(CD16) interaction with ligand induces Ca<sup>2+</sup> mobilization and phosphoinositides turnover in human natural killer cells. Differential role of Ca<sup>2+</sup> in FcR(CD16) and IL-2-induced transcription and expression of lymphokine genes. **J. Exp. Med.** **1989.** **169:549-567.**
- 17) Cuturi, M.C., I. Anegon, F. Sherman, R. Loudon, J.A. Calvetti, S. C. Clark, B. Perussia, and G. Trinchieri. Production of hematopoietic colony-stimulating factors by human natural killer cells. **J. Exp. Med.** **1989.** **169:569-583.**
- 18) Trinchieri G., I. Anegon, M. Cassatella and B. Perussia. The low affinity Fc receptor for IgG on human natural killer cells and neutrophils (CD16 antigen). **In: Highlights of Modern Biochemistry, Kotyk, A., Skoda, J., Paces, V and Kostka, V., eds., VSP International Science. Zeist, The Netherlands. 1989. pp. 1203-1212.**
- 19) Perussia B., M. Cassatella, I. Anegon and G. Trinchieri. Antigenic and functional properties of two low affinity FcIgGR types: FcIgGRIII (CD16) on natural killer cells

and polymorphonuclear neutrophils and FcIgGRII (CDw32) on neutrophils and B cells. 1989. In "Leukocyte Typing IV".(Knapp Ed.) Oxford University Press. 1989. p590-595.

- 20) Bouchot O., I. Anegon, A. Romaniuk, Y. Jacques, J. Paineau and J. P. Soulillou. Interleukin 2 receptor in rat heart allograft rejection. **Transplantation**. 1989. 48:918-922.
- 21) Gascan, H., I. Anegon, V. Praloran, J. Nauler, A. Godard, Y. Jacques, and J. P. Soulillou. Constitutive production of HILDA/LIF by human tumor cell lines derived from various tissues. **J. of Immunol**. 1990. 144:2592.
- 22) Anegon I., J. F. Moreau, A. Godard, Y. Jacques, M. A. Peyrat, M. M. Hallet, G. Wong and J. P. Soulillou. Human interleukin for DA cells (HILDA) production by human activated monocytes. **Cell Immunol**. 1990. 130: 50-65.
- 23) Grolleau, D., I. Anegon, and J. P. Soulillou. Control of HILDA/LIF gene expression in activated human monocytes. **Proc. N. Y. Acad. Sci**. 1990. p 19-30.
- 24) Anegon, I., D. Grolleau and J. P. Soulillou. Regulation of HILDA/LIF gene expression in activated human monocytic cells. **J. of Immunol**. 1991. 147: 3973-3980.
- 25) Godard, A., D. Heymann,, S. Raheer, I. Anegon, M. A. Peyrat, B. Le Mauff, E. Mouray, M. Gregoire, K. Virdee, J. F. Moreau and Y. Jacques. High and low affinity receptors for human interleukin for DA cells/leukemia inhibitory factor on human cells. **J. Biol. Chem**. 1992. 267: 3214-3222.
- 26) Blancho, G., J. F. Moreau, I. Anegon and J. P. Soulillou. HILDA/LIF is present in the urine of rejecting kidney graft recipients. **Transplant. Int**. 1992. 5: 57-58.
- 27) Jacques, Y., I. Anegon, M. M. Hallet, A. Godard, J. P. Moisan and J. P. Soulillou. Les multiples facettes de la cytokine HILDA/LIF. **Médecine et Science**. 1992. 9: 939-949.
- 28) Bugeon, L., M. C. Cuturi, J. Paineau, I. Anegon and J. P. Soulillou. Similar levels of granzyme A and perforine mRNA expression in rejected and tolerated heart allografts in donor specific tolerance in rats. **Transplantation**. 1993. 56: 405-408. .
- 29) Anegon I., H. Blottiere, M. C. Cuturi, Y. Lenne, G. Trinchieri, J. Faust and B. Perussia. Characterization of a human monocyte antigen, B.148.4 regulated during cell differentiation and activation. **J. Leuk. Biol**. 1993. 53: 390-398.
- 30) Thibaudeau, K., I. Anegon, B. Lemauff, J. P. Soulillou and D. Blanchard. Human natural antibodies to porcine platelets. **Transplantation**. 1994. 57:1110-1115.
- 31) Thibaudeau, K., I. Anegon, B. Lemauff, J. P. Soulillou and D. Blanchard. Specificity of natural antibodies directed against cells from pigs. **Transplant. Proc**. 1994. 26: 1003-1005.

- 32) Cuturi, M. C., R. Josien, D. Cantarovich, L. Bugeon, I. Anegon, S. Menoret, H. Smit, P. Douillard and J. P. Soulillou. Decreased anti-donor major histocompatibility complex class I and increased class II alloantibody response in allograft tolerance in adult rats. **Eur. J. Immunol.** **1994.** **24:1627-1631.**
- 33) Bogers, M. J. M., F. Lang, K. E. Parker, B. Le Mauff, I. Anegon, Y. Jacques, and J. P. Soulillou. Rat interleukin-2 immunoglobulin M fusion proteins are cytotoxic in vitro for cells expressing the IL-2 receptor and can abolish cell-mediated immunity in vivo. **Transplantation.** **1994.** **58: 932-939.**
- 34) Anegon, I., M. C. Cuturi, A. Godard, M. Moreau, M. Terqui, F. Martinat-Botté, J. P. Soulillou. Presence of leukemia inhibitory factor and interleukin 6 in porcine uterine secretions prior to conceptus attachment. **Cytokine.** **1994.** **6: 493-499.**
- 35) Charreau, B, A. Cassard, L. Tesson, B. Le Mauff, J. M. Navenot, D. Blanchard, D. Lublin, J. P. Soulillou, I. Anegon. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or DAF. **Transplantation.** **1994.** **58: 1222-1229.**
- 36) Villers, D., T. Dao, J. M. Nguyen, E. Bironneau, A. Godard, M. Moreau, D. De Groote, F. Nicolas, J. P. Soulillou and I. Anegon. Increased plasma levels of human interleukin for DA1.a cells/leukemia inhibitory factor in sepsis correlate with shock and poor prognosis. **J. Infect. Dis.** **1995.** **171: 232-236.**
- 37) Blottière, H., G. Daculsi, I. Anegon, J. A. Poueza, P. N. Nelson, and N. Passuti. Utilization of activated U937 monocytic cells as a model to evaluate biocompatibility and biodegradation of synthetic calcium phosphate. **Biomaterials.** **1995.** **16: 497-503.**
- 38) Guérif, P., I. Anegon, B. Le Mauff, J. P. Soulillou and C. Pourcel. Screening of a pig cDNA expression-library with human serum as a mean to identify new xenoantigens. **Transplant. Proc.** **1995.** **27: 2491.**
- 39) Azzoni, L., I. Anegon, B. Calabretta and B. Perussia. Ligand binding to Fc $\gamma$ R induces *c-myc*-dependent apoptosis in IL-2-stimulated NK cells. **J. Immunol.** **1995.** **154: 491-499.**
- 40) Charreau, B., A. Cassard, L. Tesson, B. Le Mauff, D. Blanchard, D. Lublin, J. P. Soulillou and I. Anegon. Permanent expression of human CD59 and/or decay-accelerating factor by rat endothelial cells confers protection from human complement-mediated lysis. **Transplant. Proc.** **1995.** **27: 336-337.**
- 41) Burg, C, Y. Patry, J. Le Pendu, M. Moreau, L. Tesson, A. Godard, J. P. Soulillou, K. Meflah and I. Anegon. Leukemia inhibitory factor derived from rat colon carcinoma cells increases host-susceptibility to tumor growth. **Cytokine.** **1995.** **7:784-792.**
- 42) Anegon, I., A. David, B. Charreau and Jean-Paul Soulillou. Somatic gene transfer in transplantation. In "**Transplantation Biology. Cellular and Molecular Aspects**", Ed. N. L. Tilney, T. B. Strom and L. C. Paul. Raven Press, NY, NY. **1996.** **689-699.**

- 43) Azimzadeh, A., P. Wolf, M. Odeh, J. P. Beller, A. Dalmaso, M. Fabre, B. Charreau, K. Thibadeau, J. Cinqualbre, J.P. Soullillou and I. Anegon. Assesment of hyperacute rejection in a rat-to-primate cardiac xenograft: model. **Transplantation** 1996. **61:1305-1313**.
- 44) Charreau, B., L. Tesson, J.P. Soullillou, C. Pourcel and I. Anegon. Transgenesis in rats: technical aspects and models. **Transg. Res.** 1996. **5:223-234**.
- 45) Charreau, B., L. Tesson, J. Buscail, J. P. Soullillou and I. Anegon. Analysis of human CD59 tissue expression directed by the CMV-IE-1 promoter in transgenic rats. **Transg. Res.** 1996. **5:443-450**.
- 46) Mirenda, V., Charreau, B., Sigalla, J. Cassard, A., Huvelin, J. M., David, A., Soullillou, J. P., Anegon, I. Xenoreactivity in the pig islet-to-human combination, feasibility of adenovirus-mediated gene transfer into pig islets. **Transplant. Proc.** 1996. **28:808-810**.
- 47) Charreau, B., C. Blondin, C. Boisson-Vidal, J. P. Soullillou and I. Anegon. Efficiency of fucans in protecting porcine endothelial cells against complement activation and lysis by human serum. **Transplant. Proc.** 1997. **29:889-890**.
- 48) Pourcel, C., B. Charreau, B. Le Mauff, J-F. Bouhours, I. Anegon and J-P. Soullillou. La xénogreffe chez l'homme: acquis et perspectives. **Médecine et Science** 1997, **13:301-311**.
- 49) Charreau, B., L. Tesson, S. Ménoret, J. Buscail, J. P. Soullillou and I. Anegon. Production of transgenic rats for human regulators of complement activation. **Transplant. Proc.** 1997. **29:1770**.
- 50) David, A., A. Cassard, L. Tesson, G. Blancho, J. Sigalla, B. Charreau, Y. Godfrin, H. Smit, B. Le Mauff, J. P. Soullillou, and I. Anegon. In vitro and in vivo gene transfer in the rat: characterization of recombinant adenoviral vectors for rat interleukin-4 (IL-4) or interleukin-10 (IL-10) cDNA. **Transplant. Proc.** 1997. **29:1750-1751**.
- 51) Azimzadeh, A., I. Anegon, K. Thibaudeau, B. Charreau, P. Zibolt, J. Cinqualbre, J. P. Soullillou and P. Wolf. Removal of anti-Gal $\alpha$ (1,3)Gal antibodies diminishes the cytotoxic effect of primate xenoreactive antibodies on rat endothelial cells. **Transplant. Proc.** 1997. **29:2337**.
- 52) Mirenda, V., B. Le Mauff, A. Cassard, J. M. Huvelin, F. Boeffard, A. Faivre, J. P. Soullillou and I. Anegon. Intact pig pancreatic islet function in the presence of human xenonatural antibody binding and complement activation.. **Transplantation.** 1997. **63:1452-1462**.
- 53) Sigalla, J., A. David, I. Anegon, M. Fiche, F. Boeffard, J. M. Huvelin, A. Cassard, J-P. Soullillou and B. Le Mauff. Adenovirus-mediated gene transfer into isolated adult pancreatic islets. Normal beta-cell function despite induction of an anti-adenovirus immune response. **Human Gene Therapy.** 1997. **8:1625-1634**.



- 54) David, A., J. Chetritt, H. Coupel, L. Tesson, A. Cassard, G. Blancho, B. Charreau, JB. Charreau, J. Sigalla, F. Buzelin, B. Le Mauff, J. P. Soulillou and I. Anegon. Adenovirus-mediated gene transfer in rat liver of IL-4 but not of IL-10 produces severe acute hepatitis. **Cytokine**. 1997. 9:818-829
- 55) Charreau, B., S. Menoret, L. Tesson, J-P. Soulillou, I. Anegon. Generation and use of transgenic rats. **Rat Genome**. 1997. 3:125-132.
- 56) Azimzadeh, A., P. Wolf, K. Thibaudeau, J. Cinqualbre, J-P. Soulillou, I. Anegon. Comparative study of target antigens for primate xenoreactive natural antibodies in pig and rat endothelial cells. **Transplantation**. 1997. 64:1166-1174.
- 57) Charreau, B., L. Tesson, A. Cassard, P. Doulliard, B. Quantin, A. Pavirani, J.P. Soulillou, and I. Anegon. Adenovirus-mediated expression of human CD59 on xenogeneic endothelial cells: protection against human complement-mediated lysis and induction of cellular activation by adenoviral transduction. **Xenotransplantation**. 1997. 4:212-221.
- 58) Anne David, Hélène Coupel-Clauce, Jérôme Chetritt, Laurent Tesson, Armelle Cassard, Jean-Paul Soulillou and Ignacio Anegon. Anti-adenovirus immune responses in rats are enhanced by interleukin-4 but not interleukin-10 produced by recombinant adenovirus. **Hum. Gene Ther**. 1998. 9:1755-1768.
- 59) Cuturi, C., I. Anegon, R. Josien, J. P. Soulillou. Cytokines en transplantation. **Annals de l'Institut Pasteur**. 1998, 9:181-189.
- 60) Mirenda, V., B. Le Mauff, F. Boeffard, A. Cassard, N. Jugeau, J-P. Soulillou, I. Anegon. Intact pancreatic islet function despite humoral recognition in the pig-to-monkey combination. **Transplantation**. 1998. 66:1485-1495.
- 61) Josien, R., P. Douillard, C. Guillot, M. Müschen, I. Anegon, J. Chetritt, S. Ménoret, J. P. Soulillou, M. C. Cuturi. A critical role for transforming growth factor- $\beta$  (TGF- $\beta$ ) in donor transfusion-induced allograft tolerance. **J. Clin. Invest**. 1998. 102:1920-1926.
- 62) Tesson, L., S. Ménoret, B. Charreau, J-P. Soulillou, I. Anegon. Endothelial expression of FasL in transgenic rats under the temporal control of a tetracycline-inducible system. **Transplant. Proc**. 1999. 31:1533-534.
- 63) Ménoret, S., M. Jean, L. Tesson, J-P. Soulillou I. Anegon and B. Charreau,. Optimisation of cryopreservation procedures for rat embryos. **Transplant. Proc**. 1999. 31:1531-1532.
- 64) Cécile Guillot, Anne David, Hélène Coathalem, David Froud, Laurent Tesson, Philippe Moullier, B. Le Mauff, Claire Usal, Jean-Paul Soulillou, Maria Cristina Cuturi, Ignacio Anegon. Adenovirus-mediated cytokine gene transfer in heart allograft transplantation. **Biochem. Soc. Transactions**. 1999. 27:864-869.
- 65) Chetritt, J., A. David, C. Guillot, L. Tesson, C. Laboisse, J-P. Soulillou, I. Anegon. Effet protecteur in vivo d'un inhibiteur de l'interleukin 1 $\beta$  converting enzyme

- (l'YVADcmk) dans un nouveau modèle d'hépatite apoptotique induite par l'interleukine-4 produite par un adenovirus recombinant. **Gastroenterol. Clin. Biol.** **1999.** **23:1021-1027.**
- 66) Charreau, B., S. Ménoret, L. Tesson, A. Azimzadeh, M. Audet, P. Wolf, R. Marquet, C. Verbakel, J. IJzermans, P. Cowan, M. Pearse, A. d'Apice, J-P. Soulillou, I. Anegon. Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates. **Mol. Med.** **1999.** **5:617-630.**
- 67) Barreau, N., Y. Godfrin, J-F. Bouhours, J-D. Bignon, G. Karam, E. Leteissier, A. Moreau, J. Dantal, S. Ménoret, I. Anegon, B-M. Imbert, S. Brouard, J-P. Soulillou, and G. Blancho. Interaction of anti-HLA antibodies with pig xenoantigens. **Transplantation.** **2000.** **69:148-256.**
- 68) Guillot, C., B. Le Mauff, M. C. Cuturi and I. Anegon. Gene therapy in transplantation in the year 2000: moving towards clinical applications ? **Gene Ther.** **2000.** **7:14-19.**
- 69) David, A., J. Chetritt, C. Guillot, J-M. Hesslan, C. Cuturi, J-P. Soulillou, I. Anegon. Interleukin-10 produced by recombinant adenovirus prolongs survival of cardiac allografts in rats. **Gene Ther.** **2000.** **7:505-510.**
- 70) Guillot, C., P. Mathieu, H. Coathalem, B. Le Mauff, M. G. Castro\*, L. Tesson, C. Usal, T. Laumonier, S. Brouard, J-P Soulillou, P. R. Lowenstein\*, M. C. Cuturi and I. Anegon. Tolerance to cardiac allografts via local and systemic mechanisms after adenovirus-mediated CTLA4Ig expression. **J. Immunol.** **2000.** **164:5258-5268.**
- 71) Verbakel, C.A.E., I. Anegon, S. Ménoret, R.L. Marquet, J.N.M. Ijzermans. Cellular immunity overrules the protective effect of human DAF as demonstrated in an ex-vivo heart perfusion model. **Transplant. Proc.** **2001.** **33:781-782.**
- 72) Bouchet, D., L. Tesson, C. Guillot, P. Mathieu, S. Ménoret, E. Gilbert, P. Löwenstein and M. Castro and I. Anegon. Gene transfer in transplantation. Genetic engineering of vascularized grafts for FasL expression. **2001. In Vascular Endothelium: Source and Target of Inflammatory Mediators" Ed. John D. Catravas, Allan D. Callow, Una S. Ryan, and Maya Simionescu. IOS Press, Netherlands. 227-236.**
- 73) David C Kluth, Clare V Ainslie, Wayne P Pearce, Sian Finlay, Daniel Clarke, Ignacio Anegon and Andrew J Rees. Macrophages transduced with adenovirus to express IL-4 reduce inflammation in experimental glomerulonephritis. **2001. J. Immunol.** **166:4728-4736.**
- 74) Mathieu, P. C. Guillot, C. A. Gerdes, F. Buzelin, P. Lowenstein, M. Castro, J. P. Soulillou, I. Anegon. Adenovirus-mediated CD40Ig expression attenuates chronic vascular rejection lesions. **2001. Am J. of Transplantation S1:423.**
- 75) Cécile Guillot\*, Hélène Coathalem\*, Jérôme Chetritt, Anne David, Pedro Lowenstein, Emmanuelle Gilbert, Laurent Tesson, N. van Rooijen, Maria Cristina Cuturi, Jean-Paul Soulillou and Ignacio Anegon. Lethal hepatitis after gene transfer of IL-4 in the liver is independent of immune responses and dependent on apoptosis

of hepatocytes: a rodent model of IL-4 induced hepatitis. **2001. J. Immunol. 166:5225-5235.**

- both authors contributed equally to this work.

- 76) Ménoret, S., M. Jean, L. Tesson, J-P. Soulillou, I. Anegon and B. Charreau. Cryopreservation procedure for 1-cell and two-cell stage transgenic rat embryos. **2001. Transgenics 3:237-242.**
- 77) Laurent Tesson, Jean-Marie Heslan, Séverine Ménoret, and Ignacio Anegon. Rapid and accurate determination of zygosity in transgenic animals by real-time quantitative PCR. **2002. Transg. Res. 11:43-48.**
- 78) Guillot, C., C. Guillonneau, P. Mathieu, C. Gerdes, S. Ménoret, C. Braudeau, L. Tesson, K. Renaudin, M. C. Castro, P. Lowenstein, I. Anegon. Prolonged blockade of CD40-CD40L interactions by gene transfer of CD40Ig results in long-term heart allograft survival and donor-specific hyporesponsiveness but does not prevent chronic rejection. **2002. J. Immunol. 168:1600-1699.**
- 79) Aubert, D., S. Ménoret, D. E. Chiari, V. Pichard, S. Durand, L. Tesson, P. Moullier, I. Anegon and N. Ferry. Cytotoxic immune response blunts long-term transgene expression after efficient retroviral-mediated hepatic gene transfer in rat. **2002. Mol. Ther. 5:388-396.**
- 80) Bouchet, D. C. Chauveau, P. Mathieu, J-C. Roussel, C. Braudeau, L. Tesson, J-P. Soulillou, R. Buelow, I. Anegon. Inhibition of graft arteriosclerosis development in rat aortas following heme oxygenase-1 gene transfer. **Transpl. Immunol. 2002. 9:235-238.**
- 81) Mathieu, P., C. Guillot, C. Chauveau, D. Bouchet, L. Tesson and I. Anegon. Genetic engineering in allotransplantation of vascularized organs. **Current Gene Therapy. 2002. 2:9-21.**
- 82) Anegon, I. Gene therapy in transplantation. **In Encyclopedia of the Human Genome on the web. 2003. Genes and disease section. Ed. David N. Cooper. Nature Publishing Group.**
- 83) Chauveau, C.\* , D. Bouchet\*, P. Mathieu, J-C. Roussel, C. Braudeau, K. Renaudin, L. Tesson, J-P. Soulillou, R. Buelow and I. Anegon. Gene transfer of heme-oxygenase 1 and carbon monoxide delivery inhibit chronic rejection. **2002. Am. J. Transplant. 2:581-592.** \*both authors contributed equally to this work.
- 84) Ménoret, S., D. Aubert, L. Tesson, C. Braudeau, V. Pichard, N. Ferry and I. Anegon. LacZ transgenic rats tolerant for  $\beta$ -galactosidase: recipients for gene transfer studies using lacZ as a reporter gene. **2002. Hum. Gene Ther. 13:1383-1390.**
- 85) Delphine Bouchet\*, Laurent Tesson\*, Séverine Ménoret, Béatrice Charreau, Patrick Mathieu, Hideo Yagita, Ghislaine Duisit, and Ignacio Anegon. Differential sensitivity of endothelial cells of various species to apoptosis induced by gene transfer of Fas ligand: role of FLIP levels. **2002. Mol. Med.8:612-23.**  
\*both authors contributed equally to this work.

- 86) Stockmann, H., C. Verbakel, P. Okkema, F. Bonthuis, S. Ménoret, I. Anegon, R. Marquet, J. Ijzermans. No functional benefit for hDAF-transgenic rat livers despite protection from tissue damage following perfusion with human serum. **Transpl Int.** **2002. 15:595-601.**
- 87) Bruno Pitard, H  l  ne Pollard, Onnik Agbulut, Olivier Lambert, Jean-Thomas Vilquin, Yan Cherel, J  r  me Abadie, Jane-Lise Samuel, Jean-Louis Rigaud, Severine Menoret, Ignacio Anegon, and Denis Escande. A non-ionic amphiphile vector promotes gene delivery in vivo to skeletal and cardiac muscles. **2002. Hum. Gene Ther.** **13:1767-75.**
- 88) Heather M Wilson, Keith N Stewart, Paul AJ Brown, Ignacio Anegon, S. Chettibi, Andrew J Rees, David C Kluth. Bone marrow derived macrophages (BMDM) genetically modified to produce IL-10 reduce injury in experimental glomerulonephritis. **2002. Mol. Ther.** **6:710-17.**
- 89) P. Mathieu, J.C. Roussel, F. Dagenais, I. Anegon. Cartilaginous metaplasia and calcification in aortic allograft is associated with transforming growth factor  $\beta$ 1 expression. **2003; J Thorac Cardiovasc Surg.** **126:1449-54**
- 90) Peter Schmidt, Masafumi Goto, Brigitte Le Mauff, Ignacio Anegon and Olle Korsgren. Adult porcine islet cells expressing human complement regulatory proteins DAF (CD55) or CD59 are partially protected from direct complement-mediated cell lysis in human serum. **2003. Transplantation.** **75:697-702.**
- 91) Guillot, C., S. M  noret, C. Guillonneau, C. Braudeau, M. G. Castro, P. Lowenstein and I. Anegon. Active suppression of allogeneic proliferative responses by dendritic cells after induction of long term allograft survival by CTLA4Ig. **2003. Blood** **101: 3325-3333.**
- 92) Braudeau C, Bouchet D, Toquet C, Tesson L, M  noret S, Iyer S, Laboissee C, Willis D, Jarry A, Martinet B, Buelow R, Anegon I \* $\Delta$  and Chauveau C\*. Generation of heme oxygenase-1 transgenic rats. **2003. Exp. Biol. Med.** **228:466-71.** \* both authors shared senior authorship.  $\Delta$  corresponding author.
- 93) T. Laumonier, N. Potiron, F. Boeffard, C. Chagneau, S. Brouard, C. Guillot, JP Soulillou, I. Anegon and B. Le Mauff. CTLA4Ig adenoviral gene transfer induces long-term islet rat allograft survival, without tolerance, after systemic but not local intragraft expression. **2003 Hum. Gene Ther.** **14:561-75.**
- 94) J. Ashton-Chezz, G. Meurette, G. Karam, T. Petzold, D. Minault, J. Naulet, L. Tesson, M. Plat, I. Anegon, J.P. Soulillou, G. Blancho. The study of Mitoxantrone as a potential immunosuppressor in transgenic pig renal xenotransplantation in baboons; comparison with cyclophosphamide. **2004. Xenotransplantation.** **11:112-22.**
- 95) AG El-Shemi, H. Fujinaka, A. Matsuki, J. Kamiie, P. Kovalenko, Z. Qu, V. Bilim, G. Nishimoto, E. Yaoita, Y. Yoshida, I. Anegon, T. Yamamoto. Suppression of experimental crescent glomerulonephritis by interleukin-10 gene transfer. **2004. Kidney Int.** **65:1280-9.**

- 96) Hill, M., M. Bausero, D. Mazal, S. Ménoret, J. Khalife, I. Anegon and E. Osinaga. Immunobiological characterization of N-nitrosomethylurea-induced rat breast carcinomas: tumoral IL-10 expression as a possible immune escape mechanism. **2004. Breast Cancer Res. Treat. 84: 107-116.**
- 97) Braudeau, C. †, D. Bouchet †, L. Tesson, S. Iyer, S. Remy, R. Buelow, I. Anegon<sup>§Δ</sup> and C. Chauveau <sup>Δ</sup>. Induction of long-term cardiac allograft survival by heme oxygenase-1 gene transfer. **2004. Gene Therapy. 11: 701-710.** † Both authors contributed equally to this work. Δ Both authors shared senior authorship, § corresponding author
- 98) Carole Guillonueau <sup>1</sup>, Cédric Louvet <sup>1</sup>, Karine Renaudin, Jean-Marie Heslan, Michèle Heslan, Caroline Vignes, Cécile Guillot, Yongwon Choi, Larry Turka, Maria-Cristina Cuturi, Ignacio Anegon <sup>2</sup> and Régis Josien <sup>2</sup>. The role of TNF-related activation-induced cytokine (TRANCE) – receptor activating NF-κB (RANK) interaction in acute allograft rejection and CD40L-independent chronic allograft rejection. **2004. J. Immunol. 172:1619-1629.**  
<sup>1</sup> both authors contributed equally  
<sup>2</sup> both are senior and corresponding authors
- 99) Séverine Ménoret, Martine Plat, Gilles Blancho, Françoise Martinat-Botté, Pierre Bernard, Georges Karam, Laurent Tesson, Karine Renaudin, Philippe Guillouet, Bernard Weill, Christiane Chéreau, Louis-Marie Houdebine, Jean-Paul Soulillou, Michel Terqui\*, and Ignacio Anegon<sup>\*Δ</sup>. Characterization of human CD55 and CD59 transgenic pigs and kidney xenotransplantation in the pig-to-baboon combination. **2004. Transplantation. 77:1468-1471.** \*both authors shared senior authorship. Δ corresponding author
- 100) Anegon, I., C. Guillonueau, M. Hill, and C. Chauveau. Application of gene transfer technologies to transplantation. **2004. Ther. Drug Monit. 26:248-250.**
- 101) Juliana Puppi, Carole Guillonueau, Virginie Pichard, Maria Cristina Cuturi, Ignacio Anegon and Nicolas Ferry. Long term hepatocyte transduction with retroviral vectors requires induction of immune tolerance. **2004. J. Hepatol. 41:222-228.**
- 102) N. Potiron, C. Chagneau, F. Boeffard, Jean-Paul Soulillou, I. Anegon, and B. Le Mauff. Systemic but not local expression of CTLA4Ig or CD40Ig by adenovirus-mediated gene transfer prolongs pancreatic islet survival in the rat-to-mouse combination. **2005. Cell Transplant. 14:263-75.**
- 103) C. Martin, M. Plat, V. Nerrière-Daguin, F. Coulon, L. Tesson, I. Anegon, B. Melchior, S. Uzbekova, E. Venturi, F. Condé, J-M. Hermel, P. Hantraye, B. Le Mauff, F. Boeffard, S. Sergent-Tanguy, I. Neveu, P. Naveilhan, J-P. Soulillou, M. Terqui, P. Brachet, B. Vanhove. Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation. **2005. Transgenic Res. 14:373-384.**
- 104) Carole Guillonueau, Venceslas Aubry, Karine Renaudin, Céline Séveno, Claire Usal, Katsunari Tezuka, Ignacio Anegon. Inhibition of chronic rejection and

development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L costimulation blockade. **2005. Transplantation. 80:255-63.**

**This manuscript received an Editorial comment, Brook MO, Jones ND and Wood KJ. 80:253-4.**

- 105)** Laurent Tesson, Jean Cozzi, Séverine Ménoret, Séverine Remy, Claire Usal, Alexandre Fraichard, Ignacio Anegon. Transgenic modifications of the rat genome. **2005. Transgenic Res. 14:531-46.**
- 106)** C. Chauveau, S. Remy, P-J. Royer, M. Hill, S. Tanguy-Royer, F.-X. Hubert, L. Tesson, R. Brion, G. Beriou, M. Gregoire, R. Josien, M. C. Cuturi and I. Anegon. Heme oxygenase-1 expression inhibits dendritic cell maturation and pro-inflammatory function but conserves IL-10 expression. **2005. Blood. 106; 1694-1702.**
- 107)** Louvet, C., E. Chiffolleau, M. Heslan, L. Tesson, J-M. Heslan, R. Brion, G. Bériou, C. Guillonnet, J. Khalife, I. Anegon, M-C. Cuturi. Identification of a new member of the CD20/FcεRIβ family overexpressed in tolerated allografts. **2005. Am. J. Transplant. 5:2143-53.**
- 108)** Haspot, F., C. Séveno, A. Dugast, F. Coulon, K. Renaudin, C. Usal, M. Hill, I. Anegon, M. Heslan, R. Josien, S. Brouard, J-P Soulillou, B.Vanhove. Anti-CD28 antibody induced kidney allograft tolerance related to tryptophan degradation and TCR<sup>+</sup> class II<sup>+</sup> B7<sup>+</sup> regulatory cells. **2005 Am. J. Transplant.10: 2339-48.**
- 109)** Dai, J., A. M. Guinault, C. Pages, I. Anegon, P. Desgranges, J-P. Becquemin, E. Allaire. Overexpression of transforming growth factor-beta1 stabilizes already-formed aortic aneurysms: a first approach to induction of functional healing by endovascular gene therapy. **2005. Circulation. 112:1008-15.**
- 110)** Toumaniantz, G., Seze, C., Serpillon, S., Menoret, S., Tesson, L., Anegon, I., and Gauthier, C. Vascular beta-adrenergic remodeling in rat transgenic model overexpressing endothelial beta3-adrenoceptors. **2005. Arch Mal Coeur Vaiss 98, 836-840.**
- 111)** M. Hill, V. Pereira, C. Chauveau, R. Zagani, S. Remy, L. Tesson, D. Mazal, L. Ubillos, R. Brion, K. Ashgar, M. F. Mashreghi, K. Kotsch, J. Moffett, C. Doebis, M. Seifert, J. Boczkowski, E. Osinaga and I. Anegon. Heme oxygenase-1 inhibits rat and human breast cancer cells proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. **2005. FASEB J. 19:1957-68.**
- 112)** J. M. Heslan, G. Beriou, J. B. Le Luduec, C. Guillonnet, I. Anegon, J. P. Soulillou. M. C. Cuturi, E. Chiffolleau. Accumulation of T cells with potent regulatory properties and restricted Vβ7-TCR rearrangements in tolerated allografts. **2005. Transplantation. 80:1476-84.**
- 113)** M. L. Zenclussen, I. Anegon, A. Zambon, C. Chaveau, K. Vogt, K. Gerlof, A. Sollwedel, H-D. Volk, T. Ritter, A. C. Zenclussen. Overexpression of heme oxygenase-1 by adenoviral gene transfer improves pregnancy outcome in a murine model of abortion. **2006. J. Reprod. Immunol. 69: 35-52.**

- 114) N. Gong, U. Pleyer, J. Yang, K. Vogt, M. Hill, I. Anegon, H.-D. Volk, T. Ritter. Influence of local and systemic CTLA4Ig gene transfer on corneal allograft survival. **2006. J. Gene Med. 8: 459-467.**
- 115) Curtin JF, King GD, Barcia C, Liu C, Hubert FX, Guillonneau C, Josien R, Anegon I, Lowenstein PR, Castro MG. Flt3 ligand recruits plasmacytoid dendritic cells into the central nervous system. **2006. J. Immunol. 176:3566-77.**
- 116) Gong N, U. Pleyer, K. Vogt, I. Anegon, A. Flügel, H-D.Volk, T. Ritter. Local overexpression of nerve growth factor in rat cornea transplants improves allograft survival. **2007. Invest. Opth. Vis. Sci. 48:1043-52.**
- 117) C. Guillonneau, M. Hill, F-X. Hubert, E. Chiffolleau, C. Hervé, X-L Li, M. Heslan, C. Usal, L. Tesson, S. Ménoret, A. Saoudi, B. Le Mauff, R. Josien, M. C. Cuturi and I. Anegon. CD40Ig treatment results in allograft acceptance mediated by CD8<sup>+</sup>CD45RC<sup>low</sup> T cells, IFN $\gamma$  and indoleamine 2,3 dioxygenase. **2007. J. Clin. Invest. 117 :1096-1106.**  
**This manuscript was discussed in the News and Views section of J. Clin. Invest. (J. Zhang, 2007, 117: 871-873)**
- 118) Marcelo Hill, Rachid Zagani, Cécile Voisine, Claire Usal and Ignacio Anegon. Nitric oxide indoléamine 2,3 dioxygenase mediate CTLA4Ig-induced survival of graft heart allografts in rats. **2007. Transplantation. 84: 1060-3.**
- 119) Dominique Chabannes, Marcelo Hill, Emmanuel Merieau, Julien Rossignol, Régis Brion, Jean Paul Soullillou, Ignacio Anegon and Maria Cristina Cuturi. A role for heme oxygenase 1 in the immunosuppressive effect of adult rat and human mesenchymal stem cells. **2007. Blood. 110: 3691-3694.**
- 120) Thebault P, Condamine T, Heslan M, Hill M, Bernard I, Saoudi A, Josien R, Anegon I, Cuturi MC et Chiffolleau E. Role of IFN $\gamma$  in allograft tolerance mediated by CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells by induction of IDO in endothelial cells. **2007. Am. J. Transplant. 7: 2472-82.**
- 121) M. Hill, S. Tanguy-Royer, C. Chauveau, K. Asghar, P. Royer, L. Tesson, F. Lavainne, S. Remy, R. Brion, F-X. Hubert, M. Heslan, M. Rimbart, L. Berthelot, J. Moffett, R. Josien, M. Grégoire and I. Anegon. Indoleamine 2,3-dioxygenase expands human CD4<sup>+</sup>CD25<sup>high</sup> regulatory T cells by promoting maturation of LPS-treated dendritic cells. **2007. Eur. J. of Immunol. 37:3054-62.**
- 122) Dorothée Duluc, Yves Delneste, Fang Tan, Marie-Pierre Moles, Linda Grimaud, Julien Lenoir, Laurence Preisser, Ignacio Anegon, Laurent Catala, Norbert Ifrah, Philippe Descamps, Erick Gamelin, Hugues Gascan, Mohamed Hebbar, Pascale Jeannin. Tumor-associated leukemia inhibitory factor and IL-6 skew monocyte differentiation into tumor-associated-macrophage-like cells. **2007. Blood, 110: 4319-30.**
- 123) C. Guillonneau<sup>1</sup>, C. Séveno<sup>1</sup>, A-S. Dugast, X-L. Li, K. Renaudin, F. Haspot, C. Usal, J. Véziers, I. Anegon<sup>2</sup> and B. Vanhove<sup>2</sup>. Anti-CD28 antibodies modify

regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. **2007. J. Immunol. 179: 8164-8171.**

<sup>1</sup> CG and CS contributed equally to this report and are listed in alphabetical order.

<sup>2</sup> IA and BV are both senior and corresponding authors and are listed in alphabetical order.

- 124)** Thomas Laumonier, Sheng Yang, Stephane Konig, Christine Chauveau, Ignacio Anegon, Pierre Hoffmeyer, Jacques Menetrey. Lentivirus mediated HO-1 gene transfer enhances myogenic precursor cell survival after autologous transplantation in pig. **2008. Mol. Ther. 16:404-10.**
- 125)** Xian-Liang Li, Séverine Ménoret, Brigitte Le Mauff, Mathieu Angin, Ignacio Anegon. Promises and obstacles for the blockade of CD40-CD40L interactions in allotransplantation. **2008. Transplantation. 86:10.**
- 126)** A. Toromanoff, Y. Chérel, M. Guilbaud, M. Penaud-Buldo, R.O' Snyder, M. E. Haskins, J-Y. Deschamps, L. Guigand, G. Podevin, V.R Arruda, K. A . High, H. H. Stedman, F. Rolling, I Anegon, P Moullier, C Le Guiner. Safety and efficacy of regional intravenous (RI) *versus* intramuscular (IM) delivery of rAAV1 and rAAV 1 and rAAV 8 to nonhuman primate skeletal muscle. **2008. Mol. Ther. 16: 1291-99.**
- 127)** Stéphanie Le Bas-Bernardet, Ignacio Anegon, Gilles Blancho. Progress and prospects: genetic engineering in xenotransplantation. **2008. Gene Therapy, 15:1247-56.**
- 128)** J. Cozzi, A. Fraichard, V. Braun, A-C. Gross, C. Merrouche, I. Anegon, K. Thiam. Pronuclear DNA injection for the production of transgenic rats. **2009. Methods in Mol. Biol. 561:73-88.**
- 129)** Silvia Tomat, Francesco Paolo, Russo, Maria Guido, Georgios Kechagias, Annalisa Masier, Chiara Calore, Giustina De Silvestro, Ignacio Anegon, Emanuele Cozzi, Fiorella Calabrese and Patrizia Burra. Study of the microcirculation in hDAF transgenic rat livers xenoperfused with human blood. **2009. Xenotransplantation. 16: 83-90.**
- 130)** Séverine Remy, Philippe Blancou, Laurent Tesson, Virginie Tardiff, Régis Brion, Pierre Joseph Royer, Roberto Motterlini, Roberta Foresti, Sylvie Pogu, Marc Gregoire, Jean-Marie Bach, Ignacio Anegon\* and Christine Chauveau\*. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. **2009. J. Immunol. 182:1877-84. \* both senior and corresponding authors and are listed in alphabetical order.**
- 131)** Julien Rossignol, C. Boyer, R. Thinard, S. Remy, AS. Dugast, D. Dubayle, ND. Dey, F. Boeffard, J. Delecryn, D. Heymann, B. Vanhove, I. Anegon, P. Naveilhan, GL. Dunbar, L. Lescaudron. Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation, **2009. J. of Cellular and Mol. Med. 13:2547-58.**
- 132)** Moreau A., Hill M., Thébault P., Deschamps J.Y., Chiffolleau E., Chauveau C., Rolling F., Moullier P., Anegon I., Alliot-Licht B., and Cuturi M.C. Heme



oxygenase-1 mediates the immunomodulatory effect of immature bone marrow-derived dendritic cells in vitro and in vivo both in rodents and non-human primates. **2009. FASEB J. 23:3070-7.**

- 133) A. M. Geurts, G. J. Cost, J. C. Miller, Y. Freyvert, B. Zeitler, V. M. Choi, S. S. Jenkins, A. Wood, X. Cui, X. Meng, A. Vincent, S. Lam, R. C. DeKelder, M. Michalkiewicz, R. Schilling, J. Foeckler, S. Kalloway, H. Weiler, S. Ménoret, I. Anegon, G. D. Davis, P. Sullivan, L. Zhang, E. J. Rebar, P. D. Gregory, F. D. Urnov, H. J. Jacob, and R. Buelow. Knockout rats produced via embryo microinjection of designed Zinc Finger Nucleases. **2009. Science, 325:433.**
- 134) Pamela Thebault, Natacha Lhermite, Gaëlle Tilly, Laëtitia Le Texier, Thibaut Quillard, Michele Heslan, Ignacio Anegon, Sophie Brouard, Beatrice Charreau, Maria-Cristina Cuturi and Elise Chiffolleau\*. The C-type Lectin-like Receptor CLEC-1, expressed by myeloid cells and endothelial cells, is upregulated by immunoregulatory mediators and moderates T cell activation. **2009. J. Immunol. 183:3099-108.**
- 135) Séverine Ménoret<sup>1</sup>, Laurent Tesson, Séverine Remy, Claire Usal, Anne-Laure Iscache and Ignacio Anegon. Transgenesis, recent technical developments and applications: report of a meeting in Nantes, June 8th 2009. **2009 Transgenic Res.** PMID: 19882223.
- 136) Sandra Fontaniere, Valérie Braun, Séverine Ménoret, Ignacio Anegon, Christel Merrouche, Alexandre Fraichard, Yacine Cherifi. Pronuclear injection for the production of transgenic rats. **2009. Cold Spring Harbor protocols. 561:73-88.**
- 137) Séverine Remy, Tuan Nguyen, Séverine Ménoret, Laurent Tesson, Claire Usal and Ignacio Anegon. The use of lentiviral vectors to obtain transgenic rats. **2010. Methods in Mol. Biol., 597:109-25.**
- 138) Laurent Tesson, Séverine Remy, Séverine Ménoret, Claire Usal and Ignacio Anegon. Analysis by quantitative PCR of zygosity in genetically modified organisms. **2010. Methods in Mol. Biol., 597:277-85.**
- 139) Séverine Ménoret, Séverine Remy, Claire Usal, Laurent Tesson and Ignacio Anegon. Generation of transgenic rats by microinjection of short DNA fragments. **2010. Methods in Mol. Biol., 597, 81-92.**
- 140) Geurts AM, Cost C, Remy S, Cui X, Tesson L, Usal C, Menoret S, Jacob H, Anegon I, Buelow R. Generation of gene-specific mutated rats using zinc finger nucleases. **2010. Methods in Mol. Biol., 597, 211-25.**
- 141) Philippe Blancou and Ignacio Anegon. Heme-oxygenase 1 on APCs. What else? **2010. J. Leuk. Biol. 87:185-7.**
- 142) Séverine Remy, Laurent Tesson, Séverine Ménoret, Claire Usal, Andrew M. Scharenberg and Ignacio Anegon. Zinc-finger nucleases: a powerful tool for genetic engineering of animals. **2010. Transgenic Res. 19: 745-63.**

- 143) Alice Toromanoff, Oumeya Adjali, Thibaut Larcher, Marcelo Hill, Lydie Guigand, Pierre Chenuaud, Jack-Yves Deschamps, Olivier Gauthier, Gilles Blancho, Bernard Vanhove, Fabienne Rolling, Yan Chérel, Philippe Moullier, Ignacio Anegon, Caroline Le Guiner. Lack of immunotoxicity after regional intravenous (RI) of rAAV to nonhuman primate skeletal muscle. **2010. Mol. Ther. 18:151-60.**
- 144) S. Remy, L. Tesson<sup>1</sup>, C. Usal<sup>1</sup>, S. Menoret<sup>1</sup>, V. Bonnamain<sup>1</sup>, V. Nerrière-Daguin<sup>1</sup>, J. Rossignol<sup>1</sup>, C. Boyer<sup>1</sup>, TH. Nguyen<sup>2</sup>, P. Naveilhan<sup>1</sup>, L. Lescaudron<sup>1</sup> and I. Anegon. New lines of GFP transgenic rats relevant for regenerative medicine and gene therapy. **2010. Transgenic Res. 19:363–371.**
- 145) Séverine Ménoret, Séverine Remy, Laurent Tesson, Claire Usal and Ignacio Anegon. Generation of transgenic rats using microinjection of plasmid DNA or lentiviral vectors. **2010. In “Handbook of protocols on transgenic technologies”, Ed. T. Saunders and S. Pease Ed., Springer-Verlag.**
- 146) X-L. Li, S. Ménoret, S. Bezie, L. Caron, D. Chabannes, M. Hill, F. Halary, M. Angin, M. Heslan, C. Usal, L. Liang, C. Guillonneau, B. Le Mauff, M-C. Cuturi, R. Josien, I. Anegon Mechanism and localization of CD8 regulatory T cells in a heart transplant model of tolerance. **2010. J. Immunol. 185:823-33.**
- 147) Françoise Schmitt, Séverine Remy, Anne Dariel, Maude Flageul, Virginie Pichard, Claire Usal, Anne Myara, Sophie Laplanche, Ignacio Anegon, Philippe Labrune, Guillaume Podevin, Nicolas Ferry and Tuan Huy Nguyen. Complete correction of Gunn rat with lentiviral vectors carrying miR-142 target sequences to thwart immune response. **2010. Gastroenterology. 139:999-1007.**
- 148) Ferenbach DA, Ramdas V, Spencer N, Marson L, Anegon I, Hughes J, Kluth DC. Macrophages expressing heme oxygenase-1 improve renal function in ischemia/reperfusion injury. **Mol Ther. 2010. 18:1706-13.**
- 149) Séverine Ménoret, Anne-L. Iscache, Laurent Tesson, Séverine Remy, Claire Usal, Michel J. Osborn, Gregory J. Cost, Marianne Brüggemann, Roland Buelow and Ignacio Anegon. Characterisation of immunoglobulin heavy chain knockout rats. **Eur. J. Immunol. 2010. 40: 2932-41.**  
**This manuscript received a highlight comment (R. Holmdahl, vol 40: p. 2680-81.**
- 150) Carole Guillonneau, Elodie Picarda and Ignacio Anegon. CD8+ regulatory T cells in solid organ transplantation. **Curr. Opinion in Org. Transplant. 2010. 15:751–756.**
- 151) Séverine Ménoret, Séverine Bézie, Xian-Liang Li, Claire Usal, Lise Caron and Ignacio Anegon. Tranilast, an analogue of tryptophan catabolites, induces allograft tolerance by CD161<sup>+</sup> cells. **2011. J Transl Med.; 9(Suppl 2): P27.**
- 152) Delphine Michel-Monigadon, Virginie Bonnamain, Véronique Nerrière-Daguin, Anne-Sophie Dugast, Xavier Lévêque, Martine Plat, Eric Venturi, Philippe Brachet, Ignacio Anegon, Bernard Vanhove, Isabelle Neveu, Philippe Naveilhan.

- Trophic and immunoregulatory properties of neural precursor cells: benefit for intracerebral transplantation. **2011. Exp. Neurobiology. 230:35–47.**
- 153)** Ashley T. Martino, Roland W. Herzog, Ignacio Anegon, Oumeya Adjali. Measuring immune responses to rAAV gene transfer. **2011. Methods Mol. Biol. “Adeno-associated vectors for gene therapy”, 807:259-72.**
- 154)** Ménoret, M., Carole Guillonnet, Séverine Bezie, Lise Caron, Ignacio Anegon, Xian Liang Li. Regulatory CD8+ T cells. **2011. Methods Mol Biol. 677:63-83.**
- 155)** Blancou, P., Virginie Tardiff, Thomas Simon, Séverine Remy, Leandro Carreño, Alexis Kalergis, Ignacio Anegon. Immunoregulatory properties of heme oxygenase-1. **2011. Methods Mol Biol. 677:247-68.**
- 156)** F. Lelaln, Cecile Boyer, R. Thinard, S. Remy, C. Usal, L. Tesson, I. Anegon, P. Naveilhan, P. Damier and L. Lescaudron. Effects of human alpha-synuclein A53T-A30P mutations on neurogenesis in a new transgenic rat model of Parkinson disease. **2011. Parkinson’s Disease. 987084.**
- 157)** Y Delneste, M Gregoire, MC Cuturi & I Anegon. Yin Yang of immunoregulation in organ transplantation and cancer **2011. Immunotherapy 3 (4 Suppl. 1) p1.**
- 158)** E Picarda, I Anegon & C Guillonnet. T-cell receptor specificity of CD8+ Tregs in allotransplantation. **2011. Immunotherapy 3 (4 Suppl. 1) p35.**
- 159)** Simon T, Anegon I, Blancou P. Heme oxygenase and carbon monoxide as an immunotherapeutic approach in transplantation and cancer. **Immunotherapy. 2011 Apr;3(4 Suppl):15**
- 160)** Hill M, Thebault P, Segovia M, Beriou G, Tilly G, Merieau E, Anegon I, Chiffolleau E, Cuturi C. Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through IFN- $\gamma$  and EB13. **2011. Am. J. Transplant. 11:2036-45.**
- 161)** Anegon I. Tenth anniversary issue of Current Gene Therapy. **Curr. Gene Ther. 2011 Jun 1;11(3):154.**
- 162)** L. Tesson, S. Ménoret, E. Leung, B. J. Niles, S. Remy, Y. Santiago, A. I. Vincent, X. Meng, L. Zhang, P. D. Gregory, I. Anegon<sup>1</sup>, and G. J. Cost<sup>1</sup>. Knockout rats via embryo microinjection of TAL effector nucleases. **Nature Biotechnol. 2011. 29(8):695-6.** <sup>1</sup> senior authors
- 163)** Anne-Laure Iscache, Séverine Ménoret, Laurent Tesson, Séverine Remy, Claire Usal, Christophe Pedros, Abdelhadi Saoudi, Roland Buelow and Ignacio Anegon. Effects of Bcl-2 overexpression on B cells in transgenic rats and hybridomas. **2011. International Immunol. 10:625-36.**
- 164)** Marcelo Hill, Ala-Eddine Deghmane, Mercedes Segovia, Maria Leticia Zarantonelli, Gaelle Tilly, Philippe Blancou, Gaelle Beriou, Regis Josien, Ignacio Anegon, Eva Hong, Corinne Ruckly, Aude Antignac, Meriem El Ghachi, Ivo Gomperts Boneca, Muhamed-Kheir Taha, Maria Cristina Cuturi. Penicillin binding

proteins as danger signals; meningococcal PBP2 activates dendritic cells through TLR4. **2011. PlosONE. 6(10):e23995.**

- 165)** F. M, Herrero E, T. J, R. E, Flaquer M, Gomà M, Lloberas N, Anegon I, Cruzado JM, Grinyó JM, Herrero-Fresneda I. Mesenchymal stem cell therapy prevents IFTA in a rat kidney allograft model. **2012. Stem Cells and Develop. 21:3125-35.**
- 166)** A. A. Herrada, C. Llanos, J. P. Mackern Oberti, L. J. Carreño, C. Henriquez, R. S. Gómez, M. A Gutierrez, I. Anegon, S. H. Jacobelli and Alexis M. Kalergis. Heme oxygenase-1 expression is altered in monocytes from systemic lupus erythematosus patients. **2012, Immunology. 136(4):414-24.**
- 167)** Virginie Bonnamain, Elodie Mathieux, Reynald Thinard, Paméla Thébault, Véronique Nerrière-Daguin, Xavier Lévêque, Ignacio Anegon, Bernard Vanhove, Isabelle Neveu and Philippe Naveilhan. Expression of heme oxygenase-1 in neural stem/progenitor cells as a potential mechanism to evade host immune response. **2012, Stem Cells. 30:2342-53.**
- 168)** Angin M, Poirier N, Dilek N, Le Guiner C, Toromanoff A, Blancher A, Chereil Y, Renaudin K, Blancho G, Vanhove V, Anegon I, Le Mauff B. Gene transfer of human CD40Ig does not prevent rejection in a non-human primate kidney allotransplantation model. **2012. Transplant Immunol. 27(4):139-45**
- 169)** Séverine Ménoret, Sandra Fontanière, Derek Jantz, Laurent Tesson, Reynald Thinard, Séverine Remy, Claire Usal, Laure-Hélène Ouisse, Alexandre Fraichard, Ignacio Anegon. Generation of *Rag1* knockout immunodeficient rats and mice using engineered meganucleases. **2012. FASEB J. 27(2):703-11.**
- 170)** Thomas Simon, Sylvie Pogu, Virginie Tardiff, Kevin Rigaud, Séverine Remy, Eliane Piaggio, Nicolas Escirou, Jean-Marie Bach, Ignacio Anegon and Philippe Blancou. Carbon monoxide-treated dendritic cells decrease beta1-integrin induction on CD8(+) T cells and protect from type 1 diabetes. **2013. Eur. J. Immunol. 43:209-18.**
- 171)** Michael J Osborn, Biao Ma1, Suzanne Avis, Ashleigh Binnie, Jeanette Dilley, Xi Yang, Kevin Lindquist, Séverine Ménoret, Anne-Laure Iscache, Laure-Hélène Ouisse, Arvind Rajpal, Ignacio Anegon, Michael S. Neuberger, Roland Buelow and Marianne Brüggemann. High affinity IgG antibodies develop naturally in Ig-knockout rats carrying germline human IgH/Igκ/Igλ loci bearing the rat CH region. **2013. J. Immunol. 190(4):1481-90.**
- 172)** Julie Hervé, Laurence Dubreil, Virginie Tardif, Mickael Terme, Sylvie Pogu, Ignacio Anegon, Bertrand Rozec, Chantal Gauthier, Jean-Marie Bach and Philippe Blancou. β2-adrenoreceptor agonist inhibits antigen cross-presentation by dendritic cells. **2013. J. Immunol. 190:3163-71.**
- 173)** Dusan Popadic, Ignacio Anegon, Dominique Baeten, Hermann Eibel, Thomas Giese, Per Marits, Eva Martinez-Caceres, Françoise Mascart, Frank Nestle,

- Ricardo Pujol-Borrell, Emina Savic; Carmen Scheibenbogen; Barbara Seliger; Sara Thunberg; Maureen Turina, Federica Villanova, Ola Winqvist, Ann-Charlotte Wikström. Predictive immunomonitoring - the COST ENTIRE initiative. **2013. Clin. Immunol. 147:23-6.**
- 174)** Marianne Brüggemann, Michael J. Osborn, Biao Ma, Suzanne Avis, Ashleigh Binnie, Ignacio Anegon and Roland Buelow. Transgenic animals derived by DNA microinjection. **2013. Handbook of Therapeutic Antibodies, Janice Reichert & Stefan Dübel, Eds, 2<sup>nd</sup> ed. Wiley-VCH.**
- 175)** Juan Mackern-Oberti, Carolina Llanos, Leandro Carreño, Sebastián Riquelme, Ignacio Anegon, Sergio Jacobelli, Alexis Kalergis. Carbon monoxide exposure improves immune function in lupus prone mice. **2013. Immunology. 140:123-32.**
- 176)** Anegon I. "It is not superstition that worries me, Herr Doctor, but genes and chromosomes" Inspector Kemp, from the movie Young Frankenstein, 1974. **2013. Curr. Gene Ther. May 16. PMID:23688002**
- 177)** V. Tardif, S. A. Riquelme, S. Remy, L. J. Carreño, C. M. Cortés, T. Simon, M. Hill, C. Louvet, C. A. Riedel, P. Blancou, J.-M. Bach, C. Chauveau, S. M. Bueno, I. Anegon<sup>§</sup> and A. M. Kalergis<sup>§</sup>. Carbon monoxide decreases endosome-lysosome fusion and inhibits soluble antigen presentation by dendritic cells to T cells. **2013. Eur. J. Immunol. 43:2832-44. § both senior authors**
- 178)** Séverine Ménoret, Laurent Tesson, Séverine Remy, Reynald Thinard, Claire Usal, Laure-Hélène Ouisse, Virginie Thepenier and Ignacio Anegon. Meeting Report: Technical advances in the generation of transgenic animals and in their applications. **2013. Transgenic Res. 22(5):1065-72.**
- 179)** Sullivan C, Barry FP, Ritter T, O'Flatharta C, Howard L, Shaw G, Anegon I, Murphy JM. Allogeneic murine mesenchymal stem cells: migration to inflamed joints in vivo and amelioration of collagen induced arthritis when transduced to express CTLA4Ig. **2013. Stem Cells Dev. 22:3203-13.**
- 180)** Moreau A, Varey E, Anegon I, Cuturi MC. Effector mechanisms of rejection. **Cold Spring Harb Perspect Biol. 2013 Nov 1;5(11). doi:pii: a015461. 10.1101/cshperspect.a015461.**
- 181)** Ma B, Osborn MJ, Avis S, Ouisse LH, Ménoret S, Anegon I, Buelow R, Brüggemann M. Human antibody expression in transgenic rats: comparison of chimeric IgH loci with human V<sub>H</sub>, D and J<sub>H</sub> but bearing different rat C-gene regions. **2013. J Immunol Methods. 400-401:78-86**
- 182)** Pierre Corre, Christophe Merceron, Caroline Vignes, Sophie Sourice, Martial Masson, Nicolas Durand, Florent Espitalier, Paul Pilet, Thomas Cordonnier, Jacques Mercier, Severine Remy, Ignacio Anegon, Pierre Weiss, Jerome Guicheux. Determining a Clinically Relevant Strategy for Bone Tissue Engineering: An "All-in-One" Study in Nude Mice. **2013. PlosONE, 8(12):e81599.**

- 183)** Fink, KD., Julien Rossignol, Ming Lu, Xavier Lévêque, Travis D. Hulse,<sup>1</sup> Andrew T. Crane, Veronique Nerrière-Daguin, Robert D. Wyse, Phillip A. Starski, Matthew T. Schloop, Dylan J. Dues, Steve J. Witte, Cheng Song, Ludovic Vallier, Tuan H. Nguyen, Philippe Naveilhan, Ignacio Anegon, Laurent Lescaudron and Gary L. Dunbar. Survival and differentiation of adenovirus-generated iPSCs transplanted into the rat striatum. **2014. Cell Transplantation. 23:1407-23**
- 184)** Séverine Ménoret, Laurent Tesson, Séverine Remy, Claire Usal, Virginie Thépenier, Reynald Thinard, Laure-Hélène Ouisse, Anne De Cian, Carine Giovannangeli, Jean-Paul Concordet and Ignacio Anegon. Gene targeting in rats using transcription activator-like effector nucleases. **2014. Methods, 5;69:102-7.**
- 185)** E. Mathieux, V. Nerrière-Daguin, X. Lévêque, D. Michel-Monigadon, V. Bonnamain, R. Buelow, S. Ménoret, I. Anegon, P. Naveilhan and I. Neveu. IgG response to intracerebral xenotransplantation: specificity and role in the rejection of porcine neurons. **2014. Am. J. Transplant. 14(5):1109-19.**
- 186)** V. Ponce de León, A. M. Mérillat, L. Tesson, I. Anegón, E. Hummler. Generation of TALEN-mediated GRdim knockin rats by homologous recombination. **2014. PlosONE, 9(2):e88146.**
- 187)** Picarda, S. Bézie, V. Venturi, K. Echasserieau, E. Merieau, A. Delhumeau, K. Renaudin, S. Brouard, K. Bernardeau, I. Anegon and C. Guillonnet. Donor MHC-derived peptide recognized by TCR biased-CD8<sup>+</sup> Tregs suppresses organ rejection. **2014. J. Clin. Invest, 124:2497-512.**
- 188)** Anegon I. Editorial. In 2013 Gene Therapy is a Nike; for 2014, Just Do It! **Curr. Gene Ther. 2014 Feb;14(1):1.**
- 189)** M. Segovia, C. Louvet, P. Charnet, A. Savina, G. Tilly, L. Gautreau, L. Carretero-Iglesia, G. Beriou, I. Cebrian, T. Cens, L. Hepburn, E. Chiffolleau, R. A. Floto, I. Anegon, S. Amigorena, M. Hill and M. C. Cuturi. Autologous dendritic cells prolong allograft survival through Tmem176b-dependent antigen cross-presentation. **2014. Am. J. Transplant. 14(5):1021-31.**
- 190)** S. Remy, L. Tesson, S. Menoret, C. Usal, A. De Cian, V. Thepenier, R. Thinard, R. Buelow, G. Cost, C. Giovannangeli, A. Fraichard, J-P. Concordet, I. Anegon. Efficient homologous recombination in rat zygotes using TALE nucleases. **2014. Genome Res. 24:1371-83.**
- 191)** Mackern-Oberti JP, Riquelme SA, Llanos C, Schmidt CB, Simon T, Anegon I, Jara E, Riedel CA, Bueno SM, Kalergis AM. Heme oxygenase-1 as a target for the design of gene and pharmaceutical therapies for autoimmune diseases. **2014. Curr. Gene Ther. 14:218-35.**
- 192)** T. Larcher, A. Lafoux, L. Tesson, S. Remy, V. Thepenier<sup>3</sup>, V. François, C. Le Guiner, H. Goubin, M. Dutilleul, L. Guigand, A. De Cian, C. Boix, J. B. Renaud, Y. Cherel, C. Giovannangeli, J-P. Concordet, I. Anegon<sup>+</sup>, C. Huchet<sup>+</sup>. Characterization

of dystrophin deficient rats: a new model for Duchenne muscular dystrophy. **2014. PLoS ONE, 9(10):e110371. +both senior and corresponding authors**

- 193)** Abarrategui-Pontes C, Créneqy A, Thinard R, Fine E, Thepenier V, Fournier Le ray L, Cradick TJ, Bao G, Tesson L, Podevin G, Aneqon I, Nguyen TH. Codon swapping of zinc finger nucleases confers expression in primary cells and *in vivo* from a single lentiviral vector. **2014. Curr. Gene Ther. 14:365-76.**
- 194)** Aurélie Moreau, Céline Vandamme, Mercedes Segovia, Marie Devaux, Mickaël Guilbaud, Gaëlle Tilly, Nicolas Jaulin, Johanne Le Duff, Yann Cherel, Jack-Yves Deschamps, Ignacio Aneqon, Philippe Moullier, and Maria-Cristina Cuturi, Oumeya Adjali. Generation and *in vivo* evaluation of IL10-treated dendritic cells in a nonhuman primate model of AAV-based gene transfer. **Molecular Therapy - Methods & Clinical Development. 2014 1:14028.**
- 195)** M. Crispo, M. Vilariño, PC. dos Santos-Neto, R. Núñez-Olivera, F. Cuadro, N. Barrera, AP. Mulet, TH. Nguyen, I. Aneqon and A. Menchaca. Embryo development, fetal growth and postnatal phenotype of eGFP lambs generated by lentiviral transgenesis. **2015. Transgenic Res. 24:31-41.**
- 196)** Aneqon, I. New humanized mouse model of bronchiolitis obliterans syndrome. **2015. Transplantation. 99:468-469**
- 197)** B. Ranchoux, F. Antigny, C. Rucker-Martin, A. Hautefort, C. Péchoux, H. Jan Bogaard, P. Dorfmueller, S. Menoret, F. Lecerf, S. Planté, S. Chat, E. Fadel, A. Houssaini, I. Aneqon, S. Adnot, G. Simonneau, M. Humbert, S. Cohen-Kaminsky, and F. Perros. Endothelial-to-mesenchymal transition in pulmonary hypertension. **2015. Circulation. 131:1006-18.**
- 198)** S. Bézie, E. Picarda, L. Tesson, K. Renaudin, J. Durand, S. Ménoret, E. Mérieau, Elise Chiffolleau, C. Guillonueau, L. Caron, I. Aneqon. Fibrinogen-like protein 2/fibroleukin induces long-term allograft survival in a rat model through regulatory B cells. **2015. PLoS ONE. 10(3):e0119686.**
- 199)** I. Aneqon, T. H. Nguyen. Genes don't care ! **Curr. Gene Therapy. 2015. 15:1-2.**
- 200)** J. Bellec, M. Bacchetta, D. Losa, I Aneqon, M. Chanson and T. H. Nguyen. *CFTR* inactivation by lentiviral vector-mediated RNA Interference and CRISPR-Cas9 genome editing in human airway epithelial cells. **Curr. Gene Ther. 2015. 15(5):447-59.**
- 201)** Bézie, S., Picarda, E., Ossart, J., Tesson, L., Usal, C., Renaudin, K., Aneqon, I.\*, and Guillonueau, C\*. Interleukin-34, a new Treg-specific cytokine mediator of transplant tolerance. **2015. J. Clin. Invest., 125(10):3952-64. \* both corresponding authors**
- 202)** M. Crispo\*, AP. Mulet, L. Tesson, N. Barrera, F. Cuadro, PC. dos Santos-Neto, TH. Nguyen, A. Creneguy, L. Brusselle, I. Aneqon\* and A. Menchaca\*. Efficient generation of myostatin knock-out sheep using CRISPR/Cas9 technology

and microinjection into zygotes. **2015. PLoS ONE. Aug 25;10(8):e0136690. doi: 10.1371/journal.pone.0136690. eCollection 2015.\* both corresponding authors.**

- 203)** J. C. Martin, G. Beriou, M. Heslan, C. Bossard, A. Jarry, A. Abidi, P. Hulin, S. Menoret, R. Thinard, I. Anegon, C. Jacqueline, B. Lardeux, F. Halary, J-C. Renaud, A. Bourreille, R. Josien. IL-22BP is produced by eosinophils in human gut and blocks IL-22 protective actions during colitis. **Mucosal Immunol. 2015. Sep 2. doi: 10.1038/mi.2015.83.**
- 204)** S. Ménoret, L. Tesson, S. Remy, C. Usal, L-H. Ouisse, L. Brusselle, V. Chenouard, T. H. Nguyen, L. David, I. Anegon. Meeting report. Transgenic animals and genetic engineering techniques. **2015. Transgenic Res. 24:1079-85.**
- 205)** S. Ménoret, A. De Cian, L. Tesson, S. Remy, C. Usal, J-B. Boulé, C. Boix, S. Fontanière, A. Crénéguy, T. H. Nguyen, L. Brusselle, R. Thinard, D. Gauguier, J-P. Concordet, Y. Cherifi, A. Fraichard, C. Giovannangeli, I. Anegon. Homology-directed repair in rodent zygotes using Cas9 and TALEN engineered proteins. **2015. Scientific Reports. 5:14410.**
- 206)** S. A. Riquelme, J. Pogu, I. Anegon, S. M. Bueno and A. M. Kalergis. Carbon monoxide impairs mitochondria-dependent endosomal maturation and antigen presentation in dendritic cells. **2015. Eur. J. Immunol. 45:3269-88.**
- 207)** Durand J, Huchet V, Merieau E, Usal C, Chesneau M, Remy S, Heslan M, Anegon I, Cuturi MC, Brouard S, Chiffolleau E. Regulatory B cells with a partial defect in CD40 signaling and overexpressing granzyme B transfer allograft tolerance in rodents. **2015. J Immunol. 195(10):5035-44.**
- 208)** S. Bézie, E. Picarda, J. Ossart, B. Martinet, I. Anegon and C. Guillonnet. Compensatory regulatory networks between CD8<sup>+</sup>, T, B and myeloid cells in organ transplantation tolerance. **2015. J. Immunol. 195:5805-15.**
- 209)** A. Blasimme, I. Anegon, J-P. Concordet, J. De Vos, A. Dubart-Kupferschmitt, M. Fellous, P. Fouchet, N. Frydman, C. Giovannangeli, P. Jouannet, J-L. Serre, J. Steffann, E. Rial-Sebbag, M. Thomsen & A. Cambon-Thomsen. Genome Editing and Dialogic Responsibility: What's in a Name ? **The Am. J. Bioethics, 2015; 15:12, 54-57.**
- 210)** Tesson L, Remy S, Ménoret S, Usal C, Thinard R, Savignard C, De Cian A, Giovannangeli C, Concordet JP, Anegon I. Genome Editing in Rats Using TALE Nucleases. **2016. Methods Mol Biol.1338:245-59.**
- 211)** J-B. Renaud, C. Boix, M. Charpentier, A. De Cian, L. Perrouault, L. Tesson, R. Thinard, S. Menoret, S. Fontaniere, J. Edouard, N. de Crozé, A. Fraichard, Y. Cherifi, F. Sohm, I. Anegon, J-P. Concordet, C. Giovannangeli. Improved genome editing efficiency and flexibility using modified oligonucleotides with TALEN and CRISPR-Cas9 nucleases. **2016. Cell Rep. 14(9):2263-72.**



- 212) A. Menchaca, I. Anegon, B. Whitelaw, H. Baldassarre, M. Crispo. New tools for genetically engineered (GE) sheep and goats. **2016. Theriogenology. 86(1):160-9.**
- 213) Ignacio Anegon and Tuan H. Nguyen. “My life needs editing” (Mort Sahl) and genome editing needs ethics. **2016. Curr. Gene Therapy. 16(1):1-2.**
- 214) Vanessa Chenouard, Lucas Brusselle, Jean-Marie Heslan, Séverine Remy, Séverine Ménoret, Claire Usal, Laure-Hélène Ouisse, Tuan Huy NGuyen, Ignacio Anegon and Laurent Tesson. A rapid and cost-effective method for genotyping genome-edited animals: a heteroduplex mobility assay using microfluidic capillary electrophoresis. **2016. J. Genetics and Genomics. 43(5):341-8.**
- 215) Tuan H. Nguyen and Ignacio Anegon. Successful correction of hemophilia by genome editing in vivo using CRISPR/Cas9: delivery vector and immune responses are the key. **2016. EMBO Med. J. 8(5):439-41.**
- 216) C. J. Jung<sup>§</sup>, S. Ménoret<sup>§</sup>, L. Brusselle, L. Tesson, C. Usal, V. Chenouard, S. Remy, L-H. Ouisse, N. Poirier, B. Vanhove, P. J. de Jong<sup>\*</sup>, I. Anegon<sup>\*</sup>. Comparative analysis of *piggyBac*, CRISPR/Cas9 and TALEN-mediated BAC transgenesis in the zygote for the generation of humanized *SIRPA* rats. **2016. Scientific Rep. 6:31455. \*both senior and corresponding authors**
- 217) Ignacio Anegon and Tuan Huy Nguyen. Report meeting: 21<sup>st</sup> Nantes Actualités Transplantation (NAT). “When Stem Cells Meet Immunology”. **2016. Transplantation. 101(1):12-16.**
- 218) Simon, S., Maud Charpentier, Ignacio Anegon, Nathalie Labarriere. Immunotherapies in transplantation and cancer: 22nd NAT meeting/2nd NAT LabEx IGO joint meeting; 1-2 June 2017, Nantes, France. 2017. **Immunotherapy Sep;9(11):867-870. doi: 10.2217/imt-2017-0094. PMID: 29338607 DOI: 10.2217/imt-2017-0094**
- 219) Laure-Hélène Ouisse, Laetitia Gautreau-Rolland, Marie-Claire Devilder, Mickael Osborn, Melinda Moyon, Jonathan Visentin, Franck Halary, Marianne Bruggemann, Roland Buelow, Ignacio Anegon<sup>\*</sup>, Xavier Saulquin<sup>\*</sup>. Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies. **2017. BMC Biotechnology, 17(1):3. \* both senior and corresponding authors**
- 220) Carole Guillonau, Laurent David and Ignacio Anegon. Improved analyses of CD8+ T cell specificities using multimers of peptide MHC complexes coupled to DNA barcodes. **2017. Transplantation. 101(2):219-221.**
- 221) Picarda E., S. Bézie, L. Boucault, E. Autrusseau, S. Kilens, D. Meistermann, B. Martinet, V. Daguin, A. Donnart, E. Charpentier, L. David, I. Anegon<sup>\*</sup> and C. Guillonau<sup>\*</sup>. Transient antibody targeting of CD45RC induces transplant tolerance

- and potent antigen-specific regulatory T cells. **2017. J. Clin. Invest. Insight. 9;2(3):e90088. \* both senior and corresponding authors.**
- 222)** C. Guillonneau, S. Bézie, I. Anegon. Immunoregulatory properties of the cytokine IL-34. **2017. Cellular and Molecular Life Science. 74: :2569-2586.**
- 223)** Maria-Dolores Lopez-Robles, Annaick Pallier, Virginie Huchet, Laetitia Le Texier, Severine Remy, Cecile Braudeau, Laurence Delbos, Aurelie Moreau, Cedric Louvet, Carole Brosseau, Pierre Joseph Royer, Antoine Magnan, Franck Halary, Regis Josien, Maria-Cristina Cuturi, Ignacio Anegon, and Elise Chiffolleau. Cell-surface C-type lectin-like receptor CLEC-1 dampens dendritic cell activation and downstream Th17 responses. **2017. Blood Advances. 1(9):557-568.**
- 224)** Thomas Simon, Julien Pogu, Séverine Rémy, Frédéric Brau, Sylvie Pogu, Maud Maquigneau, Jean-François Fonteneau, Bernard Vanhove, Gilles Blancho, Eliane Piaggio, Ignacio Anegon\* and Philippe Blancou\*. Inhibition of effector antigen-1 specific T cells by intradermal administration of heme oxygenase-1 inducers. **2017. J. Autoimmunity. 81:44-55. \* both senior and corresponding authors.**
- 225)** Janyra A. Espinoza, Miguel A. Leon, Pablo F. Cespedes, Roberto S. Gomez, Gisela Canedo-Marroquin, Sebastian A. Riquelme, Francisco J. Salazar-Echegarai, Phillippe Blancou, Thomas Simon, Ignacio Anegon, Margarita K. Lay, Pablo A. Gonzalez, Claudia A. Riedel, Susan M. Bueno and Alexis M. Kalergis. Heme Oxygenase-1 Modulates Human Respiratory Syncytial Virus Replication and Lung Pathogenesis during Infection. **2017. J. Immunology. 199(1):212-223.**
- 226)** Ignacio Anegon. A new marker for regulatory macrophages. **2017. Transplantation, 101:2659-2660.**
- 227)** Alexis M. Kalergis, Ignacio Anegon, and Pablo A. González. FOCIS goes South: Advances in translational and clinical immunology. **2017. Immunotherapy. 9:789-792**
- 228)** Paula Carasi, Ernesto Rodríguez, Valeria da Costa, Sofía Frigerio, Natalie Brossard, Verónica Noya, Carlos Robello, Ignacio Anegón and Teresa Freire. Heme-oxygenase-1 expression contributes to the immunoregulation induced by fasciola hepatica and promotes infection. **2017. Frontiers in Immunol. 8:883.**
- 229)** S. Ménoret, Laurent Tesson, S. Remy, C. Usal, L-H. Ouisse, L. Brusselle, V. Chenouard, I. Anegon. Advances in transgenic animal models and techniques. **2017. Transg. Res. 26:703-708.**
- 230)** Séverine Remy, Vanessa Chenouard, Laurent Tesson, Claire Usal, Séverine Menoret, Lucas Brusselle, Jean-Marie Heslan, Tuan Huan Nguyen, Jeremy Bellien, Jean Merot, Anne de Cian, Carine Giovannangeli, Jean-Paul Concordet et Ignacio Anegon. Generation of gene-edited rats by delivery of CRISPR/Cas9 protein and donor DNA into intact zygotes using electroporation. **2017. Sci. Rep. 7:16554.**

- 231) Charpentier M, Khedher A1, Menoret S, Brion A, Lamribet K, Dardillac E, Boix C, Perrouault L, Tesson L, Gény S, Decian A, Itier JM, Anegon I, Lopez B, Giovannangeli C and Concordet JP. CtIP fusion to Cas9 enhances transgene integration by homology-dependent repair. **2018. Nat. Com. 9:1133.**
- 232) J. Gergen, F. Coulon, A. Creneugy, N. Elain-Duret, A. Gutierrez, O. Pinkenburg, E. Verhoeyen, I. Anegon, T. H. Nguyen, F. A. Halary, F. Haspot. Multiplex CRISPR/Cas9 system impairs HCMV replication by excising an essential viral gene. **2018. Plos One. 15;13:e0192602.**
- 233) S. Bézie, D. Meistermann, L. Boucault, S. Kilens, J. Zoppi, E. Autrusseau, A. Donnart, V. Nèrière-Daguin, F. Bellier-Waast, E. Charpentier, F. Duteille, L. David, I. Anegon\* and C. Guillonnet\*. Ex vivo expanded human non-cytotoxic CD8+CD45RC<sup>low/-</sup> Tregs efficiently delay skin graft rejection and GVHD in humanized mice. **2018. Frontiers in Immunology. 8:2014. \*both senior and corresponding authors.**
- 234) S. Ménoret, L-H. Ouisse, L. Tesson, F. Delbos, D. Garnier, S. Remy, C. Usal, J-P. Concordet, C. Giovannangeli, V. Chenouard, L. Brusselle, E. Merieau, V. Daguin, F. Duteille, F. Bellier-Waast, A. Fraichard, T. H. Nguyen and I. Anegon. Generation of immunodeficient rats with *Rag1* and *Il2rg* gene deletions and human tissue grafting models. **2018. Transplantation. 102:1271-1278.**
- 235) S. Bézie, I. Anegon\* and C. Guillonnet\*. Advances on CD8<sup>+</sup> Tregs and their potential in transplantation. **2018. Transplantation. 102 (9), 1467-1478. \*both senior and corresponding authors.**
- 236) J. Ossart, A. Moreau, E. Autrusseau, S. Ménoret, J. C. Martin, M. Besnard, L-H. Ouisse, L. Tesson, L. Flippe, K. Kisand, P. Peterson, F-X. Hubert, I. Anegon, R. Josien and C. Guillonnet. Breakdown of immune tolerance in AIRE-deficient rats induces a severe APECED-like auto-immune disease. **2018. J. Immunol. 201:874-887.**
- 237) L.-H. Ouisse, S. Remy, A. Lafoux, T. Larcher, L. Tesson, V. Chenouard, C. Guillonnet, L. Brusselle, N. Vimond, K. Rouger, Y. Péréon, A. Chenouard, C. Gras-Le Guen, C. Braudeau, R. Josien, C. Huchet, I. Anegon. Immunological characterization of a rat model of Duchenne's disease and demonstration of improved muscle strength after anti-CD45RC antibody treatment. **2018. bioRxiv. doi: <https://doi.org/10.1101/407023>**
- 238) Vince N, Poschmann J, Josien R, Anegon I, Limou S, Gourraud PA. 23rd Nantes Actualités Transplantation: Genomics and Immunogenetics of Kidney and Inflammatory Diseases - Lessons for Transplantation. **2019. Transplantation. 2019 May;103(5):857–861. PMID: 30399125.**
- 239) S. C. Clarke, N. D. Trinklein, U. Schellenberger, M. Osborn, B. Ma, L-H. Ouisse, A. Boudreau, L. Davison, K. E. Harris, H. Ugamraj, A. Balasubramani, B. Buelow, K. Dang, S. Iyer, B. Jorgensen, H. Ogana, D. Pham, P. Pratap, U. Rangaswamy, P. Sankaran, O. Vafa, I. Anegon, W. van Schooten, R. Buelow, S.

Force Aldred, M. Bruggemann. Multispecific Antibody Development Platform Based on Human Heavy Chain-Only Antibodies. **2019. Front. in Immunol. 9:3037.**

- 240)** M. Segovia, S. Russo, M. Jeldres, Y. D. Mahmoud, V. Perez, M. Duhalde, P. Charnet, M. Rousset, S. Victoria, F. Veigas, C. Louvet, B. Vanhove, R. A. Floto, I. Anegon, M. C. Cuturi, M. R. Girotti, G. A. Rabinovich and M. Hill. Targeting TMEM176B enhances antitumor immunity and augments the efficacy of immune checkpoint blockers by unleashing inflammasome activation. **2019. Cancer Cell. in press.**
- 241)** J. Pogu, S. Tzima, G. Kollias, N. Glaichenhaus, I. Anegon and P. Blancou, T. Simon,. Genetic restoration of heme-oxygenase-1 expression in protects from type 1 diabetes in NOD mice. **2019. Int. J. Mol. Sci. 20(7). pii: E1676.**
- 242)** M. Lambert, V. Capuano, A. Boet, T. Bertero, M. K. Nakhleh, S. Remy, L. Tesson, I. Anegon, C. Pechoux, A. Hautefort, C. Rucker-Martin, B. Manoury, V. Domergue, O. Mercier, B. Girerd, D. Montani, F. Perros, M. Humbert, and F. Antigny. Characterization of Kcnk3-mutated rat, a novel model of pulmonary hypertension **2019. Circulation Res. 125:678-695.**
- 243)** L-H. Ouisse, S. Remy, A. Lafoux, T. Larcher, L. Tesson, V. Chenouard, C. Guillonneau, L. Brusselle, N. Vimond, K. Rouger, Y. Péréon, A. Chenouard, C. Gras-Le Guen, C. Braudeau, R. Josien, C. Huchet, I. Anegon. Immunophenotype of a rat model of Duchenne's disease and demonstration of improved muscle strength after anti-CD45RC antibody treatment. **2019. Front. Immunol. 10:2131.**
- 244)** M. Kenawi, E. Rouger, M-L. Island, P. Leroyer, F. Robin, L. Tesson, S. Remy, I. Anegon, K. Nay, F. Derbré, P. Brissot, M. Ropert, T. Cavey, O. Loréal. Ceruloplasmin deficiency does not induce macrophagic iron overload: lessons from a new rat model of hereditary aceruloplasminemia. **2019. Faseb J. 33, 13492-13502.**
- 245)** L. Flippe, S. Bézie, I. Anegon\*, C. Guillonneau\*. Future prospects for CD8+ regulatory T cells in immune tolerance. **2019. Immunological Rev. in press. \* both senior and corresponding authors.**
- 246)** S. Bézie, B. Charreau, N. Vimond, J. Lasselin, N. Gérard, V. Nerrière-Daguin, F. Bellier-Waast, F. Duteille, I. Anegon\* and C. Guillonneau\*. Human CD8<sup>+</sup> Tregs expressing a MHC-specific chimeric antigen receptor display enhanced suppression of human skin rejection and GVHD in NSG mice. **2019. Blood Adv. 3:3522-3538. \* both senior and corresponding authors.**
- 247)** Gualdoni, G.S., Patricia V. Jacobo, Cristian M. Sobarzo, Cecilia V. Pérez, María E. Matzkin, Christian Höcht, Mónica B. Frungieri, Marcelo Hill, Ignacio Anegon, Livia Lustig, Vanesa A. Guazzone. Role of indoleamine 2,3-dioxygenase in testicular immune-privilege. **2019. Frontiers Immunol. 9:15919.**
- 248)** M. Gaillard, H. Tranchart, P. Lainas, O. Trassard, S. Remy, I. Anegon, A. Dubart-Kupperschmitt, and I. Dagher. Improving Hepatocyte Engraftment Following Hepatocyte Transplantation Using Repeated Reversible Portal Vein Embolization in

Rats. **Liver Transpl.** 2019, (1):98-110. **Erratum: Liver Transpl.** 2019 Jun;25(6):975. doi: 10.1002/lt.25483.

- 249) E. Dreano, M. Bacchetta, J. Simonin, L. Galmiche, C. Usal, L. Slimani, J. Sadoine, L. Tesson, I. Anegon, J-P. Concordet, A. Hatton, L. Vignaud, D. Tondelier, I. Sermet-Gaudelus, C-H. Cottart, M. Chanson. Characterization of two rat models of cystic fibrosis - KO and F508del CFTR - generated by Crispr-Cas9. 2019. **Animal Models Exp Med.** 2:297-311.
- 250) S. Ménoret, L-H. Ouisse, L. Tesson, S. Remy, C. Usal, A. Guiffes, V. Chenouar, P-J. Royer, G. Evanno, B. Vanhove, E. Piaggio, and I. Anegon. In vivo analysis of human immune responses in immunodeficient rats. 2020. **Transplantation.** 104: 715–723.
- 251) Manaud, G., E. J. Nossent, M. Lambert, M-R. Ghigna, M D. Vinhas, B.t Ranchoux, S. J. Dumas, A. Courboulin, B. Girerd, F. Soubrier, J. Bignard, O. Claude, F. Lecerf, A. Hautefort, M. Florio, B. Sun, S. Nadaud, S. E. Verleden, S. Remy, I. Anegon, H-J. Bogaard, O. Mercier, E. Fadel, G. Simonneau, A. V. Noordegraaf, K. Grünberg, M. Humbert, D. Montani, P. Dorfmueller, F. Antigny, and F. Perros. Comparison of human and experimental pulmonary veno-occlusive disease. 2020. **Am. J. Respir. Cell Mol. Biol. Mar 25.** doi: 10.1165/rcmb.2019-0015OC.
- 252) Adigbli\*, G., S. Ménoret\*, Amy R Cross, PhD\*, Joanna Hester, F. Issa\*\*, I. Anegon\*\*. Humanization of immunodeficient animals for the modelling of transplantation, graft-versus host disease and regenerative medicine. 2020. **Transplantation.** 104(11):2290-2306. \*authors contributed equally. \*\*both senior and corresponding authors.
- 253) Fourrier, F. Delbos, S. Menoret, C. Collet L. T. Thi Thuy, A. Myara, F. Petit, L. Tolosa, S. Laplanche, M. J. Gómez-Lechón, P. Labrune, I. Anegon, L. Vallier, D. Garnier, T. H. Nguyen. Regenerative cell therapy for the treatment of hyperbilirubinemic Gunn rats with fresh and frozen human iPSCs-derived hepatic stem cells. 2019. **Xenotransplantation.** (1):e12544. doi: 10.1111/xen.12544.
- 254) Caudal, D., V. François, A. Lafoux, M. Ledevin, I. Anegon, C. Le Guiner, T. Larcher and C. Huchet. Characterization of brain dystrophins absence and impact in dystrophin-deficient *Dmd<sup>mdx</sup>* rat model. 2020. **PlosOne.** in press.
- 255) Menchaca A\*, dos Santos-Neto PC, Souza M, Cuadro F, Mulet AP, Tesson L, Chenouard V, Guiffès A, Heslan JM, Gantier M, Anegon I\*, Crispo M\*. Otoferlin gene editing for a human deafness model in sheep via CRISPR-assisted ssODN-mediated Homology Directed Repair. 2020. **Scientific Rep.** 10(1):5995. doi: 10.1038/s41598-020-62879-y. \* corresponding authors.
- 256) L. Boucault, M-D. Lopez Robles, A. Thiolat, S. Bézie, M. Schmueck-Henneresse, C. Braudeau, N. Vimond, A. Freuchet, E. Austrousseau, F. Charlotte, R. Redjoul, F. Beckerich, M. Leclerc, E. Piaggio, R. Josien, H-D. Volk, S. Maury, J. L Cohen, I. Anegon\* and C. Guillonnet\*. Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease. 2020. **Blood Adv.** 4. 2501-2515. \* both senior and corresponding authors.

- 257) Rannou, A., G. Toumaniantz, T. Larcher, I. Leroux, M. Ledevin, A. Hivonnait, C. Babarit, R. Fleurisson, L. Dubreil, S. Ménoret, I. Anegon, F. Charpentier, K. Rouger, L. Guével, Human MuStem cell grafting into infarcted rat heart attenuates adverse tissue remodeling and preserves cardiac function. **2020. *Molecular Therapy - Methods & Clinical Development*. 18:446-463.**
- 258) Bézie, C., A. Freuchet, C. Sérazin, A. Salama, S. Usal, N. Vimond, I. Anegon\* and C. Guillonnet\*. IL-34 actions on FOXP3+ Tregs and CD14+ monocytes control human graft rejection. **2020. *Front. Immunol.* 11:1496. \* both senior authors.**
- 259) Bromberg, J., C. Baan, J. Chapman, I. Anegon, DC, Brennan, A. Chakera, AS. Chong, EK. Geissler, C. Guillonnet, N. Heaton, DA. Hasselink, W. Jassem, C. Jones, B. Kaplan, CL. Kaufman, W. Lim, Y. Ma, E. Massey, DB. Ostrander, Mark S. Slaughter Stefan Tullius Piotr Witkowski Germaine Wong. The Impact of COVID-19 on the state of clinical and laboratory research globally in transplantation in May 2020. **2020. *Transplantation*. 104:2252-2257.**
- 260) Dhot J, Ferron M, Prat V, Persello A, Roul D, Stévant D, Guijarro D, Piriou N, Aillerie V, Erraud A, Toumaniantz G, Erfanian M, Tesse A, Grabherr A, Tesson L, Menoret S, Anegon I, Trochu JN, Steenman M, De Waard M, Rozec B, Lauzier B, Gauthier. Overexpression of endothelin b3-adrenergic receptor induces diastolic dysfunction in rats. **2020. *ESC Heart failure*. in press. DOI: doi: 10.1002/ehf2.13040.**
- 261) Vimond, N. J. Lasselin, I. Anegon, C. Guillonnet and S. Bézie. Genetic engineering of human and mouse CD4<sup>+</sup> and CD8<sup>+</sup> Tregs using lentiviruses encoding chimeric antigen receptors. **2020. *Mol. Ther. Methods and Clinical Developments*. in press.**
- 262) Szabó, PJ J. Ebner, X. König, O. Hamza, S. Watzinger, S. Trojanek, D. Abraham, H. Todt, H. Kubista, K. Schicker, S. Remy, A. Kiss, I. Anegon, B. K. Podesser, K. Hilber. Cardiovascular phenotype of the *Dmd*<sup>mdx</sup> rat – a suitable animal model for Duchenne muscular dystrophy. **2021. *Disease Models & Mechanisms*, in press.**
- 263) Kalds, P. M. Crispo, C. Li, L. Tesson, I. Anegon, Y. Chen, X. Wang, and A. Menchaca. Generation of Double-muscled Sheep and Goats by CRISPR/Cas9-mediated Knockout of the Myostatin Gene. **2021. *Meth. Mol. Biol.* in press.**
- 264) Crispo, M., V. Chenouard, P. dos Santos-Neto, L. Tesson, M. Souza, J-M. Heslan, F. Cuadro, I. Anegon and A. Menchaca. Generation of a human deafness sheep model using the CRISPR/Cas system. **2021. *Meth. Mol. Biol.* in press.**
- 265) Freuchet, A. A. Salama, S. Remy, C. Guillonnet and I. Anegon. IL-34 and CSF-1, deciphering similarities and differences at steady state and in diseases. **2021. *J. Leuk. Biol.* in press.**
- 266) Amini, L, J. Greig, M. Schmueck-Henneresse, H-D. Volk, S. Bézie, P. Reinke, C. Guillonnet, D. L. Wagner, I. Anegon. Super-Treg: towards a new era of adoptive Treg therapy enabled by genetic modifications. **2021. *Front. Immunol.* in press.**

- 267) Ayala, MV, Bender, S, Anegon, I, Menoret, S, Bridoux, F, Jaccard, A, Sirac, C. A rat model expressing a human amyloidogenic immunoglobulin kappa light chain. 2021. **Amyloid. in press.**

## **Patents and licences.**

Know-how transfer of the technology of rat transgenesis to the biotech company genOway (2000).

### Licences:

- commercialization de rats transgéniques GFP pour la compagnie genOway (2008).
- commercialization d'un anticorps anti-IDO1 to Hycult (2008).
- Licences through MTAs for Dmd KO rats to Brystol Myers Squibb (2015) and Bamboo Therapeutics (2016), Serepta (2019).

Contracts of services for genetically modified rats through the platform Transgenesis Rat ImmunoPhenomic-Nantes (TRIP-Nantes) with companies and academic groups.

**Patents:** <https://patents.justia.com/inventor/ignacio-anegon>

- 1) **WO2015150491**, 01/04/2014: An isolated donor MHC-derived peptide and uses thereof.
- 2) **WO2015150492**, 01/04/2014: An isolated donor MHC-derived peptide and uses thereof.
- 3) **WO2016009041**, 17/07/2014: An isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases. **Licence to AbolerIS Pharma in negotiation.**
- 4) **WO2016016442**, 01/08/2014: A CD45RC<sup>+</sup> T cell depleting antibody for use in preventing transplant rejection and treating autoimmune diseases. **Licensed to AbolerIS Pharma**
- 5) **WO2016066618**, 28 oct. 2014: Compositions and methods for antigen-specific tolerance.
- 6) **EP15.305.715.3**, 12.05.2015. Methods and kits for labeling, detecting and isolating Foxp3<sup>+</sup> regulatory T cells, isolated population of Foxp3<sup>+</sup> Treg cells thus obtained and uses thereof.
- 7) **EP 15.306.092.6**, 03/07/2015: Methods for obtaining regulatory T cells and uses thereof. **Licensed to Sangamo.**
- 8) **WO2017042170A1**. 07/09/2015: A new subpopulation of human CD8<sup>+</sup>CD45RC<sup>low</sup> Tregs and uses thereof. **Licensed to Sangamo.**
- 9) **U.S. 62/257,884**, 20/11/2015: Induction of immune responses.
- 10) **EP17305939.5**, 13/07/2017: Methods for increasing expansion and immunosuppressive capacity of a population of CD8<sup>+</sup>CD45RC<sup>low/-</sup> Tregs.
- 11) **EP17306783.6**, 15/12/2017: Treatment of monogenic diseases with an anti-CD45RC

- antibody” **Licensed to AbolerIS Pharma.**
- 12) **PCT/EP2018/055883.** 9/3/18: Nuclease fusions for enhancing genome editing by homology-directed transgene integration.
  - 13) **EP18306230.6,** 21/09/2018: Anti-human CD45RC antibodies and uses thereof. **Licensed to AbolerIS Pharma.**
  - 14) **WO2015150492A2.** 14/12/2018: Isolated donor MHC-derived human peptides and uses thereof for stimulating and activating the suppressive function of CD8+CD45RC<sub>low</sub> Tregs.
  - 15) **20190255077.** Methods for Treating Heart Transplant Rejection.
  - 16) **EP19305039.0,** 14/01/2019: Human monoclonal antibodies binding to HLA-A2
  - 17) **EP19305046.5,** 15/01/2019: Interleukin-34 (IL-34) polypeptides and uses thereof in therapy. **Licence to AbolerIS Pharma in negotiation.**
  - 18) **EP20305298.0.** 17/02/2020. Chimeric antigen receptor specific for human CD45RC and uses thereof. **Licensed to AbolerIS Pharma.**